

MEDICINE

NEWS FROM THE DEPARTMENT OF MEDICINE

MATTERS

MESSAGE FROM THE CHAIR

APRIL 2024

 UVA Health | DEPARTMENT OF MEDICINE

MISSION

We are dedicated to preventing disease and treating illness, educating and inspiring future leaders in the field of internal medicine, and supporting innovative biomedical research.

VALUES

We strive for a sense of community, connection, and synergy among all faculty, staff, and trainees.

PLEDGE

We will conform to the highest ethical standards, uphold the values of our partner organizations, and give back to our community through public service.



As I look back at my nearly 15 years as Department Chair, one of the areas that I am most proud of is the growth and excellence in the Division of Hematology and Oncology. Fifteen years ago, the Division was relatively small, with minimal research and searching for an identity. Under the leadership of Mike Williams, Karen Ballen, Tom Loughran, and many others, the Division has grown significantly, the Cancer Center now has

Comprehensive status, and the research has exploded. There is much to be excited about, and patients benefit daily from our clinicians' expertise. More than ever, the diagnosis of cancer is being transformed as new therapies make their way to the bedside. I would encourage you to read this month's newsletter to get a sense of the depth, breadth, and excellence of the Division and the care, education, and research that it delivers.

Also in this month's newsletter are the year's residency match results. I thank Dr. Brian Uthlaut and his team for their dedication and efforts in attracting the best students to join our program. As you will see, this year's class represents a diverse group of young residents who will continue the tradition of excellence in this critical program. Thanks to all who have served as interviewers as well.

Lastly, I wanted to update you on the work of the DOM Compensation Committee. The committee has now been formed and has met twice to review the basic schematic of the compensation plan. They will soon start working on developing incentive criteria. There is a tremendous amount of work to be done. Still, I am sure that under the leadership of Dr. Taison Bell, our committee will develop thoughtful recommendations that recognize the contributions of all faculty.

With best wishes,

Mitchell H. Rosner, MD, MACP
Henry B. Mulholland Professor of Medicine
Chair, Department of Medicine

[DoM WEBSITE](#) ▶

[GRAND ROUNDS](#) ▶

[HIGHLIGHTED DIVISION](#) ▶

[MINDFULLNESS MATTERS](#) ▶

[GIVE TO DOM](#) ▶

[SUBSCRIBE](#) ▶



UVA Health

DOM UPDATES & NOTES

DOM Financial Update

Department of Medicine Summary of Consolidated Financials FY21 as of February 2024

	Budget YTD	Actual YTD	\$ Variance YTD
Work RVUs	791,367	834,733	43,366
Clinical Receipts (NPSR)	50,773,576	54,228,904	3,455,328
Total Revenues	144,025,711	154,129,876	10,104,165
Total Expenditures	142,497,829	153,201,007	(10,703,178)
Net Income	1,527,883	928,870	(599,013)

Summary Explanation of Variance:

For the fiscal year through February 2024, DOM reported a consolidated net gain of \$928K and an unfavorable variance to YTD net income budget of \$599K. Clinical receipts surpassed budget by \$3.5M primarily due to strong productivity, unbudgeted Community Oncology and APP charge volumes. Total revenues include \$1.7M Endowment revenue recorded for March through June and \$1.8M clinical deficit coverage revenue accrual. Total revenue is missing \$1.3M in missing clinical agreements and revenue contingencies. Total expenditures variance is unfavorably impacted by \$5.1M increased spending related to grants and commitments, \$2.5M unbudgeted CommOnc Expenses, \$1.1M unbudgeted ICU Culpeper APPs and unbudgeted APPs night and weekend shifts and \$1.3M budgeted expenditure reduction contingencies.

Do You Have News You'd Like To Share on Medicine Matters?

Contact Kim Kelley-Wagner kak2cj@virginia.edu
434.328.0680

Welcome To The World



Congratulations to Caleb (Resident) and wife Lauren who welcomed baby Charlotte McKinney on February 26, 2024.



Congratulations to Jessica Dreicer (General Medicine) and husband Ryan McCrystal who welcomed baby Livvy Rey on March 4, 2024.

DOM UPDATES & NOTES



Rasheed Balogun MD



Monica Lawrence MD



Michelle Tran MD



Patricia Rodriguez Lozano MD



Pamela Mason MD

Awards and Achievements

Congratulations to **Dr. Rasheed Balogun** (Division of Nephrology) on receiving the American Society for Apheresis (AFSA) Presidential Award. The Awards Committee selected Dr. Balogun for his commitment to apheresis and consistency in contributing to and performing outstanding service for the Society over many years. This is a distinguished award; we are very proud of his accomplishments. [Read more...](#)

Congratulations to **Dr. Monica Lawrence** (Division of Asthma, Allergy, and Immunology), named Designated Institutional Official (DIO) and Associate Dean for Graduate Medical Education. Dr. Lawrence will supervise all GME programs, overseeing 850 residents, fellows, and trainees across our organization. [Read more...](#)

Congratulations to **Dr. Michelle Tran** (Division of Nephrology fellow), who was selected as an American Society for Nephrology Excellence in Patient Care Intern to promote the prevention and treatment of Acute Kidney Injury. [Read more...](#)

Congratulations to **Dr. Patricia Rodriguez Lozano** (Division of Cardiovascular Medicine), who has been chosen as one of the 50 learners for American College of Cardiology's (ACC) 2024-2025 Clinical Trials Research program. She will be among the 28 structural heart cardiologists and surgeons in Project REACH. [Learn more...](#)

Congratulations to **Dr. Pamela Mason and team, with the support of cardiac surgery and cardiac anesthesia**, (Division of Cardiovascular Medicine), on performing the first extravascular implantable cardioverter defibrillator (ICD) in Virginia. [Read more...](#)

FOLLOW UVA SCHOOL OF MEDICINE DIVERSITY & INCLUSION

FOLLOW UVA WOMEN IN INTERNAL MEDICINE NETWORK

In Good Health: The Nation's Hydration Fixation (A1/NPR)

Does it seem like everyone is carrying around a 30-ounce tumbler? The reusable water bottle industry is a multi-billion dollar business. But don't forget about plastics. The sales of single-use bottled water also continue to rise.

We're a nation intent on hydration. But how much of the hype around water is marketing versus science? Dr. Mitch Rosner helps answer that question and more.



LISTEN NOW

Why Are We Still Flu-ifying COVID? (The Atlantic)

COVID vaccines are now reformulated annually, and recommended in the autumn just like flu shots; tests and treatments for the disease are steadily being commercialized, like our armamentarium against flu.

Some of those decisions are "not completely unreasonable," says Costi Sifri, the director of hospital epidemiology at UVA Health, especially on a case-by-case basis. But taken together, they show how bent America has been on treating COVID as a run-of-the-mill disease—making it impossible to manage the illness whose devastation has defined the 2020s.



READ MORE

In Media

7 Quick Questions With Heart Rhythm Specialist Rohit Malhotra, MD

Dr. Malhotra, is a heart rhythm disorders specialist and cardiac electrophysiologist. He was one of the first doctors at UVA Health to implant a special type of pacemaker that doesn't use wires and instead goes directly into the heart.



[READ MORE](#)

Colon Cancer Killing Young Men, Women at Troubling Rate: Study (News Nation)



Colon cancer has become the leading cause of death among men younger than 50, and the number two cause of death in women of the same age group, according to the report, Researchers pointed to the possibility that the COVID-19 pandemic caused delays in the diagnosis and treatment of cancer in 2020 because of health care setting closures and fear of virus exposure.

Dr. Ross Buerlein, joined "NewsNation Prime" to discuss the troubling rates of colon cancer, saying regular screenings are the best form of prevention.

[WATCH NOW](#)

 **FOLLOW THE DOM**

COVID-19 vaccines: CDC says people ages 65 and up should get a shot this spring – a geriatrician explains why it's vitally important (The Conversation)

As spring 2024 fast approaches, the CDC reminds Americans that even though the public health emergency is over, the risks associated with COVID-19 are not.

Dr. Laurie Archbald-Pannone discusses the risks and recommendations.



[READ MORE](#)

CDC Guidelines for COVID Isolation Change (NBC29)

The CDC says people who test positive for COVID-19 no longer need to isolate for five days.

"We still have people dying of COVID every week at UVA," UVA Health Associate Professor of Medicine Doctor Kyle Enfield said, "So, it's not a disease that has left our environment. It just seems to be less severe now."

According to new CDC guidelines, people who test positive for COVID-19 do not need to isolate unless they have a fever.



[WATCH NOW](#)

 **Follow DOM on INSTAGRAM!**

In Media

A nagging cough can hang on for weeks or months following a respiratory illness – and there is precious little you can do about it (The Conversation)

A cough is a common symptom of these sorts of respiratory infections, and coughing is a complaint that leads to an estimated 30 million office visits every year. But a cough following an upper respiratory infection does usually go away, in time.



[READ MORE](#)

UVA Researchers Develop Online Dashboard to Help Save Children From Deadly Diarrhea

Josh Colston, PhD and team are developing a powerful online tool to save children from deadly diarrhea by detecting outbreaks sooner and accelerating the deployment of treatments and new vaccines. Diarrhea not only kills hundreds of thousands of children every year, it contributes to malnutrition and muscle wasting that stunt kids' growth, harms their mental development and helps trap them in poverty. While significant progress has been made against the disease in recent years, the UVA researchers say that the modern era of "big data" offers a vast untapped opportunity to respond more nimbly and help more children.



[READ MORE](#)

Blood Test Could Predict Risk of Long-Term COVID-19 Lung Problems (UVA Today)

Up to 30% of patients hospitalized with severe COVID-19 continue to suffer persistent symptoms months after recovering from the virus. Many of these patients develop lung scarring – some early on in their hospitalization, and others within six months of their initial illness, prior research has found.



Dr. Catherine Bonham and her collaborators wanted to better understand why this scarring occurs, determine if it is similar to progressive pulmonary fibrosis and see if there is a way to identify patients at risk.

[READ MORE](#)

With spring in full swing, UVA Health's Dr. Jeffrey Wilson discusses the factors that trigger seasonal allergies (29News)



Jeffrey Wilson
UVA PROFESSOR OF ALLERGY AND IMMUNOLOGY

The Asthma and Allergy Foundation of America says Virginia has two cities listed in the top 10 for the worst cities for people with allergies. They are Virginia Beach and Richmond.

[WATCH VIDEO](#)

In Media

Community Conversation: Dr. David Callender with UVA Health (NBC29)



Dr. David Callender discusses colorectal cancer screening with NBC29

[WATCH NOW](#)

Kate McManus, MD, Helps Us Connect With COWIMS as it turns 20



UVA School of Medicine launched COWIMS 20 years ago in 2004. Dr. McManus has been COWIMS chair since 2022.

[READ MORE](#)

New Advance Against a Form of Heart Failure Prevalent in Men (TIME)



Kenneth Walsh, PhD, and his research team discovered how Y chromosome loss triggers changes in heart immune cells that make the cells more likely to cause scarring and heart failure.

[READ MORE](#)

How Hypertrophic Cardiomyopathy Progresses in Adults (TIME)

Dr. Christopher Kramer, School of Medicine, comments on the complexities in the diagnosis and timing of hypertrophic cardiomyopathy.

“It’s an incredibly heterogeneous disease, and the more we learn about it, the more complex it gets,” he says.



[READ MORE](#)

WELCOME NEW FELLOWS!

GET A NEW PROVIDER DIRECTORY HEADSHOT

McKim Hall | Ground Floor, Room G045

Physicians and advanced practice providers: get a new or updated headshot taken in 10 minutes or less on dates listed below. No appointment needed. Bring a white coat if you have one; if not, one will be provided.

- Tuesday, April 2 | 9 a.m. - noon
- Thursday, April 11 | 11 a.m. - 2 pm
- Wednesday, April 17 | 10 a.m. - 1 p.m.
- Friday, April 26 | noon - 3 p.m.
- Monday, April 29 | 9 a.m. - noon

Social Media and Information

UVA Department of Medicine H. Charles Malpass III Memorial Grand Rounds

Friday, May 24, 2024
ERC Auditorium (or Zoom)
12 p.m.-1 p.m.



Cynthia D. Brown, MD
Professor of Clinical
Medicine
Adult Cystic Fibrosis
Director
Indiana University

Dr. Cynthia Brown joins us from Indiana University to celebrate the legacy of Dr. H. Charles Malpass III (Charlie). Dr. Malpass, an amazing father, husband, brother, son, runner, and clinician, passed away suddenly on September 14, 2023.

Charlie was renowned for his dedication as a pulmonary physician at UVA Health, specializing in interventional pulmonary and bronchoscopy. He worked tirelessly to provide diagnostic lung results and guidance for his patients, even while facing his battle with acute myeloid leukemia (AML).

Like Charlie, Dr. Brown is esteemed for her dedication to fellow education and patient care. We hope you will join us for the May 24th Grand Rounds as we remember Dr. Malpass and celebrate his enduring impact on the medical community.

MINFULNESS MATTERS A Newsletter from the UVA Mindfulness Center



UVA Resources for Team Members

support for dealing
with crisis and how to
stay informed.

**FOLLOW
UVA ID**

**FOLLOW
UVA ENDO**

**FOLLOW UVA
PULMONARY**

**FOLLOW UVA
NEPHROLOGY**

**FOLLOW
UVA CARDIO**

**FOLLOW
GASTRO**

Is Your Content Up-to-Date?

Our department websites are one of the most powerful recruitment tools we have, and to use them effectively, we need your help to keep our content up-to-date.

Please check your Division's DOM site for wherever you appear to be sure all information is current.

Researchers and lab managers, if you don't already have a research page dedicated to your team, please get in touch with Kim Kelley-Wagner to get started at kak2cj@uvahealth.org or 434.328.0680

Need a team photo or a research lab photo shoot? Contact Kim Kelley-Wagner.

Thanks for making our websites a valuable and dynamic experience!

COME SEE HOOS RUNNING WITH GIM!

'Run with GIM' (General Internal Medicine) would love for all interested to join us at 5pm every Wednesday across from the South garage on the corner of Jeanette Lancaster and Crispell Dr.

Run with GIM is a non-competitive, all-inclusive running group focused on building wellness and growing camaraderie.

DOM UPDATES & NOTES

Events

Come Out and Join and/or Ride In Support of ALS Research

Internal Medicine group will ride out in support of ALS research again this May 5th in Crozet. Anyone is welcome to join them by contacting Patrick Dillon or using the link below. Various distances are available, including a children's ride. Non-riders are also invited to the event, so please come out in support. Take a look at photos from last year!

[2024 Ride to Defeat ALS: Blue Ridge: UVA Internal Medicine - The ALS Association \(convio.net\)](https://convio.net)



STAT MADNESS

UVA's contenders include a discovery by Jeffrey Wilson, MD, PhD, and colleagues that found that sensitivity to common food allergens such as dairy and peanuts could be an important and previously unappreciated cause of deadly heart disease, even in people without obvious food allergies. That risk could equal or exceed the risk posed by smoking.

Voting in the first round of STAT Madness continues for seven days, and the championship round concludes April 4 - so there's still time! Make sure to vote UVA every day!



DEPARTMENT OF MEDICINE
MEDICINE GRAND ROUNDS
UNIVERSITY OF VIRGINIA

In Media



Photo By Elle Hogan

Do Good at Work: How Hank Brings Joy to Students, Team Members, and Patients

Joy Hilton Early wears two hats at UVA Health. One: at UVA School of Medicine, where she's served for more than 14 years as the Director of Education for the Department of Medicine – managing educational administrators and coordinators for the department's graduate and undergraduate medical education programs.

The other hat: Joy, along with her three-and-a-half-year-old English Labrador retriever, Hank, are weekly Pet Therapy Program volunteers at UVA Health.

In 2020, when Joy brought Hank home when he was just eight weeks old, she wasn't intending to raise a therapy dog – Hank was Joy's pandemic puppy.

Joy knew Hank was going to be a big dog, and she wanted to ensure he was well behaved, especially around Joy and her husband Stephen's eight grandchildren.

[Read entire article in CONNECT](#)

White House Leaders Visit UVA Comprehensive Cancer Center Following President Biden's State of the Union Address

The White House is partnering with the University of Virginia as part of President Biden's Cancer Moonshot, a national effort to end cancer. On Thursday evening in advance of Biden's State of the Union address before Congress, the administration announced that UVA's is one of 40 comprehensive cancer centers and community oncology practices that have committed to using new patient navigation services paid for by seven of the nation's leading health insurance companies. The services are designed to help patients and their caregivers more easily understand and access the complicated cancer treatment process.

[Read More...](#)



left to right: **Thomas Loughran Jr., MD**, director of UVA Cancer Center; Blake Herring, cancer services administrator; Danielle Carniva, deputy assistant to the President for the Cancer Moonshot and deputy director for health outcomes of the White House Office of Science and Technology Policy; Catherine Terrell, RN, director of Emily Couric Clinical Cancer Center Clinical Operations, Leigh Cantrell, MD, oncology physician service line lead; and **Karen Ballen, MD**, chief of hematology/oncology and medical director of the stem cell transplantation program.

WELCOME ALL!













Happy Match 2024! Below is the roster of our newest University of Virginia residency-matched class (aka The Class of 2027)! It is an outstanding group, and we are excited to welcome you to the program this summer!

This is now year 4 of virtual interviews and our second that included optional in-person open houses in February. Many thanks to our residents, faculty reviewers and interviewers, admin team, and especially our chief residents—Kara Harrison, Joe Mort, John Popovich, and Margo Tanner for all their hard work in welcoming, interviewing, and teaching more than 500 interviewees. This year’s group is distinguished academically and in leadership and service. It is one of our most geographically widespread matches, so please welcome these new physicians as they become part of the UVA family and contribute to our missions of patient care, education, research, diversity, equity, and community engagement.

Brian Uthlaut MD
 Associate Professor of Medicine
 Residency Program Director and Vice Chair of Education
 Department of Medicine

2024 - 2025 Medicine PGY 1 (Interns) CATEGORICAL

 Evan Adler USF	 Owen Battel Florida Int'l	 Stephen Chandler UAB	 Rachel Cruz Nieves USF	 Tsola Efejuku U Texas- Galveston	 Liesl Eibschutz Dartmouth	 Margaux Everingham Drexel	 Alexander Freidinger Chicago Medical	 Emma Gray Univ. S. Carolina	 Jonathan Grubbs UNC
 Connor Horne Univ. S. Carolina	 Sarah Joseph Emory	 Rachel Keller Univ Florida	 Allie Lords Univ. Washington	 Christopher Ludlow Univ. S. Carolina	 Allison Meadows MUSC	 Lily Mirfakhraie Harvard	 Nicholas Mouser Wake Forest	 Julie Okorn Michigan State	 Matthew Osborne VCU
	 Elena Parcell UVA	 Forrest Parrott Wake Forest	 Olivia Reszczyński MUSC	 Anha Telluri George Washington	 Megan Waguespack LSU	 Benjamin Witman UVA	 Drew Wodecki UC Davis	 Valerie Yang Texas Tech	

ABIM RESEARCH			PRIMARY CARE			OPHTHALMOLOGY			
 Brian Ogendi Michigan State	 Oom Pattarabanjird UVA	 Zein Aburish VCU	 Desna Ghatalia Univ. New Mexico	 Jack Hibbard Indiana U		 Matthew Griffin Drexel	 Grant Horn Case Western	 Erika Robinson UVA	 Mariana Dodd Emory
PRELIMINARY						NEUROLOGY			
 Kanupriya Gupta Univ. Pittsburgh	 Iris Harrison Univ. Florida	 Katherine Salisbury Wake Forest	 Greg Atafo Univ. of Ghana	 Alecca Como Oakland U	 Julian Gordon ECU	 Morgan Ketchersid Lincoln Memorial	 Nandini Mishra Rutgers	 Caroline Menton FSU	

HAPPY MATCH DAY

LEARN MORE & WATCH VIDEO

Education Update



From left: Joy Hilton Early – Director of Education, Department of Medicine Lizzie Daniels – Pulmonary/Critical Care Fellowship Coordinator
Brittany Davis – Gastroenterology and Transplant Hepatology Fellowship Coordinator
Terry Bennett – GME Compliance Manager for the Department of Medicine

ACGME Conference Presentations

Department of Medicine's central education team members traveled to Orlando in early March to participate in this year's annual ACGME (Accreditation Council for Graduate Medical Education) conference – "Meaning in Medicine."

In addition to participating in various plenary and workshop sessions, team members Joy Hilton Early, Terry Bennett, Brittany Davis, and Lizzie Daniels were presenters for two conference workshops.

Utilizing Instagram and Creating Your Brand: The Ultimate Recruitment Tool – Presentation by Brittany and Lizzie

Workshop Description

Graduate medical education (GME) recruitment has transformed from an in-person experience to a virtual platform. Programs and applicants have had to learn to navigate and prosper in a virtual recruitment world. The use of technology has been critical in doing so. Social media has become an effective tool that is being utilized to create a program's digital presence and reach its target audience. One social media platform that is being used by many GME programs across the country is the notorious Instagram.

Brittany and Lizzie discussed the transformation of GME recruitment to a virtual platform and its dependence on technology. They provided a roadmap for programs that utilize Instagram as the ultimate recruitment tool. They discussed the importance of building a program's brand and creating a digital presence for their target audience. They also provided tools for developing content and best practices for engaging on the social media platform. It was noted that Instagram can be used to advertise and promote your program's offerings to applicants and showcase your program, institution, geographic location, and day-to-day life as a trainee.



Lizzie (left) and Brittany (right) in front of their workshop screen and taking a selfie with participants in the background

the ACGME's accreditation model ("the Next Accreditation System") and Milestones Project. The intent was to demonstrate the relevancy of Milestones' achievement to program support staff members and to elevate their professional acumen and graduate medical education (GME) reputation.

Roadmap to Recognition – Building Our Professional Reputation One Milestone at a Time – Presentation by Joy, Terry, and Brittany

Workshop Description

In 2013, the University of Virginia's Medicine Education Team crafted "Milestones for Program Administrators" concurrent with the ACGME's accreditation model ("the Next Accreditation System") and Milestones Project. The intent was to demonstrate the relevancy of Milestones' achievement to program support staff members and to elevate their professional acumen and graduate medical education (GME) reputation.

Flash forward to 2024

Workshop Description

In this workshop, presenters described the scenario leading up to, during, and following the COVID-19 pandemic and the need to re-evaluate their core competencies and milestones for program administrators in a similar fashion to the ACGME's Milestones 2.0 updates. The workshop included a brief background and history of how their team of GME administrators collaborated to review and revise the Milestones, focusing on areas that required updates to their roles (e.g., technical skills around virtual learning/recruitment and challenges to well-being posed by remote and/or hybrid work models). They presented data gathered from their pilot project, whereby program administrators and supervisors from across the country utilized their milestones to conduct self-assessments and draft professional development "smart goals." Also, they presented sample "smart goals" and solicited participant discussion and feedback on the proposed milestones. They aim to partner with others in the GME community to solidify program administrators' professional status and credibility by creating standardized milestones that local institutions, subspecialty associations, and national accreditation entities will ultimately endorse.



Katie Christie (Neurology Education Coordinator), Lizzie, and Brittany pictured with Jason Reminick, CEO and Founder of Thalamus (a residency application and interview management platform)

DIVISION OF HEMATOLOGY & ONCOLOGY

Message from Karen Ballen MD, Division of Hematology & Oncology Chief



I am so proud to present the accomplishments of our incredible Hematology/Oncology team. We have had another banner year in clinical care, research, education, and community engagement.

In the past year, we have had the good fortune to recruit four new clinical faculty, with two physicians starting this coming summer. Dr. Danny Reed, who trained with us at UVA, joined us in our growing Leukemia program. Dr. Muneeb Rehman, a Gastrointestinal Oncology specialist, is an integral member of our very busy GI Oncology Team. Dr. Krithika Shanmugasundaram, a Chimeric Antigen Receptor (CAR)-T cell expert, recently joined our busy Stem Cell Transplant program. Dr. Balraj Singh is pioneering our expansion into Northern Virginia, working at Prince William and Culpeper. This summer, we are excited to welcome Dr. Nate Roberts, one of our Heme/Onc fellows, who will join our Lymphoma Team. Dr. Ludi Cavalcante, a sarcoma expert, will lead our Medical Sarcoma program and expand our Phase I effort—many thanks to our Administrative Specialists and Search Committees for the time and hard work of successful recruitment.

Congratulations and thanks to our Advance Practice Provider lead, Jessica Kassay-McAllister and Susie Herndon. Our APP program continues to expand. APPs Scott Cook, Kristen Noonan, Jordyn Sewell, and Jenea Brown are joining our team this year.

Our Cancer Service Line, is led by Dr. Mike Williams, former Division Chief, an international lymphoma expert, and my mentor, friend, and neighbor. Mike has transitioned to this role but remains active in mentorship, education, and scholarship. We welcome and congratulate Dr. Leigh Cantrell on her role as our Cancer Service Line Lead.

We are exceedingly proud that 22 of our providers were recognized for achieving Press-Ganey scores above the 90th percentile. UVA Oncology clinics in Augusta, Culpeper, and Pantops all achieved the coveted Number 1 honor for UVA Ambulatory clinics.

In basic research, we welcomed Dr. Todd Fox and Dr. Danielle Cook and their teams to our Hematology/Oncology Division. We now have a growing team of basic and translational investigators as part of our UVA Cancer Center led by Dr. Tom Loughran. Our Translational Orphan Blood Cancer Research Initiative (TOBRI) led by Dr. Owen O'Connor studies novel treatments for rare blood cancers, including T-cell lymphoma.

In clinical research, we have 78 open clinical research treatment trials. We are grateful to the many friends of the Cancer Center and Hematology/Oncology who provide philanthropic support for our research efforts and also help improve access to clinical trials.

In education, we thank Dr. Rick Hall for the fantastic leadership of our Hematology/Oncology fellowship program. We congratulate Dr. Trish Millard, who will be assuming leadership of our fellowship program in July 2024. Rick has been honored with a new leadership role with the Promotions Committee in the Department of Medicine. In undergraduate medical education, Dr. John Densmore has successfully led the program at Inova, and the students have had another fantastic match year.

We continue to work towards greater engagement with our community and dedication to diversity and equity. It was great to see our team at a Community Service project in the vegetable gardens of Morven Farms.

It is wonderful to have the opportunity to highlight our team's accomplishments. I am most grateful for the best colleagues ever! We appreciate such fantastic colleagues in other divisions and departments and our wonderful nurses, division staff, research coordinators, and other team members. You all make my job and our vital work so special and fun.

~Karen K. Ballen, MD

DIVISION OF HEMATOLOGY & ONCOLOGY

Disease Updates



Medical Oncology

The medical oncology section concluded a productive clinical and academic year. At the beginning of the new academic year, the section welcomed Dr. Muneeb Rehman, a new GI medical oncologist. After a long search, we have successfully recruited Dr. Ludi Cavalcante to join the Division as the new head of the medical sarcoma program and her role as Associate Director of the Phase I program.

Selected academic highlights include the completion of three investigator-initiated trials in the last year, including the POWER trial led by Dr. Trish Millard, which was presented at the San Antonio Breast Cancer Symposium, the Focused Ultrasound plus pembrolizumab trial (Breast-48) and the Entinostat plus capecitabine trial (Breast-49) led by Dr. Dillon which were also presented at national meetings.

Drs. Ryan Gantzler and Rick Hall were site PIs and co-authors on two separate phase III trials; both presented as late-breaking abstracts in the Presidential Symposium at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain, in Fall 2023. Dr. Hall was one of the top enrollers on the TROPION-Lung01 trial of datopotamab deruxtecan for second-line metastatic NSCLC presented at the ESMO meeting. Dr. Gantzler was the highest enroller in North America and co-author on the ESMO abstract and simultaneous publication in Annals of Oncology for the MARIPOSA-2 trial of amivantamab plus chemotherapy for EGFR-mutated lung cancer.

Dr. William Skeleton mentored Drs. Soham Ali and Kathyryn Fortune both presented posters at the ASCO GU meeting in San Francisco.

~ Robert Dreicer, MD

Melanoma/and related disorders

Drs. Liz Gaughan and Varinder Kaur
APP: Jennifer Eccles, Jenea Brown

Breast Medical Oncology

Drs. Christiana Brenin, Patrick Dillon and Trish Millard
APP: Paul "Mike" Marshall and Melody Noble

Thoracic Medical Oncology

Drs. Ryan Gantzler and Richard Hall
APP: Marie Thomas

Head and Neck Oncology

Dr. Varinder Kaur
APP: Jenea Brown

Gastrointestinal Medical Oncology and Unknown Primary Neoplasms

Drs. Tri Le, Paul Kunk, Muneeb Rehman, and Matthew Reilley
APP: Jenna Ally and Jenna Campo

Genitourinary Medical Oncology

Drs. Michael Devitt, Robert Dreicer, William Paul Skelton, Paul Viscuse
APP: Jennifer Eccles and Katie Stiebing

Sarcoma

Dr. Michael Douvas
Dr. Ludi Cavalcante (joining July 2024)

Infusion/Urgent Care

APP: Elizabeth Coyman, Rachel Chai, and Elizabeth Lester

Disease Updates



Stem Cell Transplant

The Stem Cell Transplant and Cellular Therapy Program continues to grow. We continue to increase our referrals from all over Virginia, including Virginia Beach, Northern Virginia, and Appalachia / SW Virginia. We have two outreach clinics and want to expand our outreach in other areas. We now have patients from different regions, including West Virginia. We perform transplants for various hematologic malignancies, including plasma cell dyscrasias, non-Hodgkin's lymphoma, Hodgkin lymphoma, acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders, as well as for bone marrow failure states. Our chimeric antigen receptor (CAR) T program is continuing to grow (up more than 25% over the last year), we have access to all FDA approved CART products, and our research CART portfolio continues to grow. We can perform some transplants safely as outpatients. We are a core center with the Blood

and Marrow Transplant Clinical Trials Network (BMT CTN) to open cooperative group clinical trials at UVA for our patients. We are well represented at the recent Transplant and Cellular Therapy meetings and the American Society of Hematology, with several presentations by our faculty.

~John Wagner, MD

Stem Cell Transplant

Drs. Karen Ballen, Krithika Shanmugasundaram, Indumathy Varadarajan, Leonid Volodin and John Wagner
APP: Hania Bushnaq-Aloul, Jessica Kassay-McAllister, and Christine Noonan
APP Inpatient: Isabel Burgess, Scott Cook, Mary Faith Dudley, Kristine Gillis, Erin Harr, and Jordyn Sewell

Hematologic Malignancies

The Hematologic Malignancy Program continues to grow in patient care and research. We are excited to welcome Dr. Roberts to our lymphoma program this summer. Drs. Ayers, Marchi, Portell, and Williams have had several international presentations on lymphoma. The clinical trial portfolio continues to increase in both B-cell and T-cell lymphoma. Dr. Keng has expanded our quality program, is a global figure in cancer quality, and serves as inpatient medical director. Dr. El Chaer has had several international presentations focusing on measurable residual disease. Dr. El Chaer also serves as the Medical Director of Infusion. Dr. Douvas is an active educator focusing on the complex young adult population. Dr. Garrett-Bakelman is studying epigenetics and older patients with Acute Myeloid Leukemia. In myeloma, Drs. Densmore and Foster are focusing on novel strategies for this population, with many new treatment options for these patients, including cellular and antibody-based therapy.

Lymphoma and CLL

Drs. Emily Ayers, Enrica Marchi, Craig Portell, and Michael E. Williams,
Dr. Nate Roberts (joining August 2024)
APP: Kim Conrad

Myeloma

Drs. John Densmore and Laahn Foster

Leukemia

Drs. Michael Douvas, Firas El Chaer, Francine Garrett-Bakelman, Michael Keng,
and Daniel Reed
APP: Kim Conrad and Amelia Hodson

DIVISION OF HEMATOLOGY & ONCOLOGY

Disease Updates



Classical Hematology

Classical Hematology has had another busy year, particularly in clinical care and education. We manage patients with complex and rare hematologic disorders and are the primary academic referral center for much of Virginia and surrounding states. As classical hematology topics span nearly all other medical and surgical specialties, we remain busy with lectures and conferences to educate medical students, residents, fellows, and other divisions and departments.

Dr. Louise Man continues to direct the grant-supported Adult Comprehensive Hemophilia Treatment Center in conjunction with colleagues in pediatrics. Dr. Davidson leads our Adult Sickle Cell Disorders program and collaborates with SCD centers around the Commonwealth to improve access to comprehensive care and raise awareness for sickle cell disease. Dr. Davidson recently attended the American Society of Hematology's Advocacy

Leadership Institute, advocating for increased funding to support sickle cell disease on Capitol Hill. In conjunction with cardiothoracic surgery, we instituted a peri-operative anemia program to manage iron deficiency in patients undergoing cardiothoracic surgery. We will expand this initiative to other surgeries with high-volume blood loss soon. Dr. Maitland continues her vital work to reduce peri-operative VTE at UVA by improving patient education and mobility. We look forward to adding two new physicians to our group in the coming year.

~Kelly Davidson, MD

Classical Hematology

Drs. Kelly Davidson, Valery Kogler, Hillary Maitland, and Louise Man

APP: Julie Armatas and Katie Gabler



UVA Community Oncology

The UVA Community Oncology Section serves patients in Fishersville and Culpeper with a spectrum of hematologic and solid tumor diagnoses. Our team oversees the multidisciplinary infusion centers at each location. The last year has seen rapid growth of clinical volumes, investments in staff expansion to maximize the use of existing space, and further alignment and integration between the community practices, medical center teams, and the academic Division. Our success in maintaining patient access for both clinic and infusion results from patient-focused teamwork, incorporation of technology, innovative problem solving, and strong relationships within the Oncology service line.

In the last year, the vault for the new linear accelerator in Culpeper was completed. Our northern oncology team is an anchor for Culpeper cancer services, and our providers are leaders on the Culpeper Medical Staff. Dr. Patel and Dr. Mahjoub piloted a successful initiative to precisely align with specific disease teams (Thoracic Oncology and Breast Oncology) at the main campus. Cancer and infusion services continue to grow in the Augusta market.

We look forward to expanding our clinical, infusion and laboratory footprint into the newly vacated space in the building. Several surgical subspecialty teams see patients in our Augusta clinic as our team works to maximize telemedicine connections to Charlottesville. This technological framework will facilitate cancer care closer to home.

~Elizabeth Gaughan, MD

Augusta Location

Drs. Gwenalyn Garcia, Nicholas Paphitis, and Mary Helen Witt

Culpeper Location

Drs. Ali Mahjoub, Pranav Patel, and Balraj Singh

APP: Michelle Otto

Charlottesville/Pantops Location

APP: Susie Herndon

Prince William/Manassas Location

Dr. Balraj Singh

DIVISION OF HEMATOLOGY & ONCOLOGY

Disease Updates



Advance Practice Providers

The APP team continues to work on template optimization with the One Access team and utilization throughout the Division. Expanding on educational opportunities by and for APPs and nursing through the educational series.

• Education Series

- A monthly, topical, lunchtime continuing education series by and for APPs and our nursing colleagues led by Jenna Campo, Rachel Chai, Julie Costin, Dr. Varinder Kaur, Marie Thomas, and Tanya Thomas. Sample presentations last year included Oncologic Emergencies by Amelia Hodson, Medical Cannabis by Jenna Campo and Jenna Ally, and Sick Cell Anemia by Katie Gabler.

• We have grown tremendously across the Division, welcoming many new APP team members.

- Jenea Brown in Head / Neck and Melanoma
- Elizabeth "Liz" Lester, DNP in the infusion center (Urgent symptom clinic / C.E.R.T)
- Elizabeth Coyman, FNP in the infusion center (Urgent symptom clinic / C.E.R.T)
- Scott Cook, NP in Stem Cell Transplant / Cellular Therapy Program (inpatient)
- Jordyn Sewell, PA in Stem Cell Transplant / Cellular Therapy Program (inpatient)
- Doctorate in Nursing
- Jess Kassay-McAllister March 2023
- Melody Noble December 2023

• Publications

- Jenna Ally, NP published in the Journal for Immunotherapy of Cancer and Daily Progress.
- Jess Kassay-McAllister, DNP published as a co-author in the Journal of Neuro-Oncology for her work in BATs clinical trial with Camilo Fadul and team and awaiting publication in the Oncology Nursing journal of her DNP project highlighting CARTOX APP use in CART therapy.

• *Couric Emergency Response Team (C.E.R.T) was developed and received approval from the resuscitation committee this past fall. We continue to grow the team to provide ACLS care and meet the needs of our higher acuity patients in the Emily Couric (EC4). This APP-led team receives specialized training and will continue to expand to our community sites in the coming years.*

~ Jess Kassay-McAllister and Susie Herndon, APP Supervisor

Updates In Hematology Hematologic Malignancies

April 12, 2024

The Forum Hotel (Kimpton)

540 Massie Road, Charlottesville

This program will explore research and advances in the diagnosis and management of benign hematologic conditions and hematologic malignancies, including indications for novel therapies and use in special populations.

Click for more information and see agenda or go to www.cmevillage.com

DIVISION OF HEMATOLOGY & ONCOLOGY

Clinical Updates

We continue to grow our clinical volumes and move more of our services to outpatient. Clinical Volumes grow yearly in all of our locations.

Clinical Volume Chart FY 2020 - FY 2023

	FY 2020	FY 2021	FY 2022	FY 2023
Inpatient Attending	13,351	14,182	14,066	13,898
Inpatient Consults	2,700	2,733	2,546	2,181
Inpatient Totals	16,051	16,915	16,612	16,079
Outpatient New and Consults	4,125	4,611	5,257	5,753
Established Outpatient Visits	40,721	43,876	47,646	53,846
Outpatient Totals	44,846	48,487	52,903	59,599


2023 Clinical Faculty Promotions



Dr. David Feith,
promoted to Professor



Dr. Paul Kunk,
promoted to Associate
Professor



Dr. Louise Man,
promoted to Associate
Professor



Dr. Matthew Reilley,
promoted to Associate
Professor

HEMATOLOGY/ONCOLOGY GRAND ROUNDS

First Wednesday each Month, 8 - 9am
Via Zoom

Educational Updates



Letter from the Program Director

We are fortunate to have an outstanding Hematology/Oncology fellowship program at the University of Virginia. Our strength lies principally in our people – first and foremost, our dedicated, thoughtful, collegial, and hard-working fellows, our outstanding program coordinator Lisa Mackey, and our committed faculty leaders.

After six years of leading our fellowship program, I will be stepping back into a supporting role as Associate Program Director (APD) while Trish Millard, MD takes over as fellowship program director in July 2024. Trish has established herself as an education leader at UVA – from residency, chief residency, fellowship, and APD of our fellowship since 2019. She will continue to grow our national presence as an education leader. Without a doubt, our program will continue to train Hematology/Oncology physicians who excel in patient care, scholarship, and education under Dr. Millard’s leadership.

~ Richard Hall, MD

Fellowship News

New Fellows

We welcomed four new fellows to the Class of 2026. Below are our first-year fellows with some of their new colleagues from left to right, **Nate Roberts MD**, **Shipra Maheshwari MD**, and **Phil. Young MD**, **Sean Dougherty MD** (UVA residency), **Valerie Tran MD** (VCU residency), **Gautham Prakash MD** (Rush Univ residency), **Fabian Bolte MD** (UVA residency), and **Chris Thomas MBBS**.




DIVISION OF HEMATOLOGY & ONCOLOGY

Educational Updates



Nate Roberts MD

Nate presented at the prestigious International Conference on Malignant Lymphoma in Lugano, Switzerland, in the summer of 2023. He is pictured (right) with his mentor, Enrica Marchi MD (left).



Jack Masur MD

Jack Masur, our 2023 Farrow and Weiss Award recipient, recently presented two posters at the GU-ASCO Annual Meeting in San Francisco, CA. Here pictured with members of the GU oncology team during the meeting (from left to right, Paul Viscuse MD, Soham Ali MD, Paul Skelton MD, Michael Devitt MD, Kathryn Fortune MD, and **Jack Masur MD**).



Shipra Maheshwari MD

Shipra was invited to attend the EGFR Resistors Lung Cancer Conference in the fall of 2023 and presented a project on caring for our EGFR positive lung cancer patients at UVA. Shipra is accompanied by her second-year colleagues at last year's fellowship graduation (L to R, Jeffrey Lantz DO, Jenna Schlefman MD, **Shipra Maheshwari MD**, Jack Masur MD).



Upcoming 2024 Graduations

We are keeping two graduates nearby and sending two graduates to be near family in Georgia and the Pacific NW. From left to right, **Phil Young MD** (Kaiser Permanente in Tacoma, WA), **Will Thomas MD** (Piedmont Cancer Institute in Newnan, GA), **Chris Thomas MBBS** (Sentara Martha Jefferson Hospital, Charlottesville, VA), and **Nate Roberts MD** (UVA lymphoma faculty).

DIVISION OF HEMATOLOGY & ONCOLOGY

Recent Events

Hematology/Oncology Spring Community Day June 3, 2023, Morven Farms



Drs. Indu Varadarajan, Louise Man, Karen Ballen and Administrator Rachael Boston with their families.



Drs. Indu Varadarajan and Bharadhwaj Kolipakkam.



Dr. Karen Ballen and Dr. Louise Man with her daughter and husband.




UVA Health

DIVISION OF HEMATOLOGY & ONCOLOGY

American Society of Clinical Oncology Annual Meeting
June 2-6, 2023, Chicago, Illinois

Hematology/Oncology Division Retreat
May 2023, Morven Farms



Drs. Paul Viscuse and William Skelton.



From left front row: Louise Man, Laahn Foster, Trish Millard, Emily Ayers, Katie Stiebing, Jenna Campo, Francine Garrett-Bakelman, Karen Ballen, Susan Herndon, Marie Thomas, Katie Gabler, Meera Kumar.

From left back row: John Wagner, Mike Keng, Leonid Volodin, Pranav Patel, Paul Viscuse, Melody Noble, Paul Kunk, Jenna Ally, Matt Reilley, Nick Paphitis, Indu Varadarajan, Liz Gaughan



Drs. Richard Hall and Lindsey Taylor (Shantzer), former Heme/Onc fellow.



From left: Mike Keng, Patrick Dillon, Muneeb Rehman, Mike Devitt, Kristine Gillis, Hania Aloul, Gwenalyn Garcia, Craig Portell, Karen Ballen, Jess Kassay-McAllister, Enrica Marchi, Mary Helen Witt, Liz Lester, Firas El Chaer, Tammy Tedsen, Danny Reed, William Skelton, Kim Conrad, Ali Mahjoub, Rachel Chai, Isabel Burgess, Emily Stubbs.



Drs. Andrew Romano (former Heme/Onc fellow), Richard Hall, Mike Devitt, and Ryan Gentzler.



DIVISION OF HEMATOLOGY & ONCOLOGY

San Antonio Breast Cancer Symposium
December 5-9, 2023, San Antonio, Texas


The 65th American Society of Hematology Annual Meeting
December 9-12, 2023, San Diego, California



Dr. Lindsey Taylor (Shantzer) former Heme/Onc fellow and Dr. Trish Millard.



From left front: Drs. Mike Keng, Laahn Foster, Firas El Chaer, Michael E. Williams, Karen Ballen, Leonid Volodin, Indu Varadarajan, Bharadhwaj Kolipakkam From left back: Drs. David Feith, Emily Ayers, Enrica Marchi, Craig Portell, Kelly Davidson, Nate Roberts



Drs. Patrick Dillon and Trish Millard



From left: Drs. Indu Varadarajan, Laahn Foster, Nate Roberts, Enrica Marchi, Firas El Chaer, David Feith, Emily Ayers, Craig Portell, Leonid Volodin, Karen Ballen, Kelly Davidson, Michael E. Williams, Mike Keng



Drs. Patrick Dillon, Trish Millard and Lindsey Taylor (Shantzer) former Heme/Onc fellow.



From left: Drs. Enrica Marchi, Craig Portell, David Feith, Karen Ballen, Firas El Chaer, Michael E. Williams, Kelly Davidson, Nate Roberts, Emily Ayers, Mike Keng, Laahn Foster, Leonid Volodin

DIVISION OF HEMATOLOGY & ONCOLOGY

Transplantation & Cellular Therapy Meeting
February 21-24, 2024, San Antonio, Texas



From left: Judy Kauffman, Glenda Royael, Kathy DeGregory, Brooke Henry, Carly Grubbs, Jessica Brandt


ASCO Gastrointestinal Cancers Symposium
January 18-20, 2024, San Francisco, California



From left: Dr. Matthew Reilley, Dr. Paul Kunk, Jenna Ally, APP, Dr. Tri Le, Dr. Muneeb, Rehman



From left: Margaret (Mimi) Pohl, Taylor Ross, Jenna Van Hoose, Leonid Volodin, Kathy DeGregory, Judy Kauffman, Brooke Henry



From left: Paul Viscuse, Soham Ali, Paul Skelton, Kathryn Fortune, Michael Devitt, Jack Masur



From left: Kathy DeGregory receives the 2024 ASTCT Pharmacy SIG Lifetime Achievement Award surrounded by her colleagues.



DIVISION OF HEMATOLOGY & ONCOLOGY

King Family Polo
August 6, 2023, Crozet, VA



From left: Drs. Nate Roberts, Valerie Tran, Sean Dougherty, Gautham Prakash, Jenna Schlefman, Fabian Bolte and Shipra Maheshwari



From left: Drs. Sean Dougherty, Valerie Tran, Gautham Prakash, and Fabian Bolte

Celebrating Excellence!



Above from left:
Enrica Marchi, MD, PhD – Excellence in Research
Indumathy Varadarajan, MD – Excellence in Clinical Care
Kelly Davidson, MD – Diversity, Equity & Inclusion Award

At right: **Leonard W. Sandridge Outstanding Contributor Award**

This award recognizes outstanding University staff or team members who demonstrate dedication to service through individual efforts, group contributions, and commitment to our larger community. It is the highest individual employee award at the University, named in honor of Leonard W. Sandridge, who was an avid champion of UVA staff and who dedicated 44 years of service to the school.

Congratulations to Janet Tillage on this well-deserved honor.



From left: Rachael Boston, Raymond Brown (HR), Nikki Carey, Janet Tillage, Tonia Duncan-Rivers (HR), Lucy Cummings (HR)



From left: Allen Burley, Dr. Trish Millard, Dr. Louise Man, Terri Fisher, Dr. Craig Portell, Rachael Boston, Jennifer Taylor, Janet Tillage, Lisa Mackey, Karen Ballen, Brooke O'Byrne, Jodi Leake, Dr. Patrick Dillon, Nazif Maqani

DIVISION OF HEMATOLOGY & ONCOLOGY

Research Updates

Research funding data

All Research Awards		
FY 2021	FY 2022	FY 2023
\$7,107,000	\$8,460,587	\$10,834,126

SELECT PUBLICATIONS

Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, **Devitt M**, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, **Dreicer R**, Gill PS. *EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma*. J Clin Oncol. 2023 Jan 20;41(3):640-650. doi: 10.1200/JCO.21.02923. Epub 2022 Aug 19. PMID: 35984996.

Barilà G, Grassi A, Cheon H, Teramo A, Calabretto G, Chahal J, Vicenzetto C, Almeida J, Shemo BC, Shi M, Gasparini VR, Munoz-Garcia N, Pastoret C, Nakazawa H, Oshimi K, Sokol L, Ishida F, Lamy T, Orfao A, Morice WG, **Loughran TP**, Semenzato G, Zambello R. *Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients*. Blood. 2023 Mar 2;141(9):1036-1046. doi: 10.1182/blood.2021013489. PMID: 36096473; PMCID: PMC10163282.

Cortese MJ, Wei W, Cerdeña S, Watkins MP, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Namoglu E, Grover NS, Snow A, Orellana-Noia V, Rainey M, Sohail M, Rudoni J, **Portell C**, Voorhees T, Landsburg DJ, Kamdar M, Kahl BS, Hill BT. *A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma*. Leuk Lymphoma. 2023 Jan;64(1):107-118. doi: 10.1080/10428194.2022.2140281. Epub 2022 Nov 2. PMID: 36323309.

Garcia JS, Flamand Y, Penter L, **Keng M**, Tomlinson BK, Mendez LM, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler C, Ho V, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberger D, Stone RM, Soiffer RJ. *Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings*. Blood. 2023 Apr 13;141(15):1884-1888. doi: 10.1182/blood.2022017686. PMID: 36332187; PMCID: PMC10122101.

Shantzer LB, **Dougherty SC**, Bolte F, Melson JW, Reed DR, Lynch AC, **Gentzler RD**, Novicoff W, Hall RD. *Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report*. Clin Lung Cancer. 2023 Mar;24(2):e60-e64. doi: 10.1016/j.clle.2022.11.006. Epub 2022 Nov 26. PMID: 36526550.

Isharwal S, **Devitt M**, Gupta S, Mithqal A, Tandon YK. *Adenosquamous carcinoma of the prostate with low PSMA expression*. Int Urol Nephrol. 2023 Mar;55(3):613-615. doi: 10.1007/s11255-022-03428-6. Epub 2022 Dec 20. PMID: 36538273.

Hess BT, Giri A, Park Y, Patel KK, Link BK, Nowakowski GS, Maliske SM, Fortin S, Chavez JC, Saeed H, Hill BT, Mejia Garcia AV, Maddocks KJ, Hanel W, Wagner- Johnston ND, Messmer MR, Kahl BS, Watkins M, Alderuccio JP, Lossos IS, Nathan S, Orellana-Noia VM, **Portell CA**, Landsburg DJ, **Ayers EC**, Castillo JJ. *Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study*. Am J Hematol. 2023 Feb;98(2):300-308. doi: 10.1002/ajh.26784. Epub 2023 Jan 1. PMID: 36588409; PMCID: PMC10107934.

McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, **Williams ME**, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. *Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program*. J Clin Oncol. 2023 Jan 10;41(2):154-162. doi: 10.1200/JCO.22.02403. PMID: 36603541.

Wang C, Chan DW, **Hendrickson EA**. Kinome-wide screening uncovers a role for Bromodomain Protein 3 in DNA double-stranded break repair. DNA Repair (Amst). 2023 Feb;122:103445. doi: 10.1016/j.dnarep.2022.103445. Epub 2022 Dec 24. PMID: 36608404; PMCID: PMC10353298.

Reed DR, Petroni GR, West M, Jones C, Alfaraj A, Williams PG, DeGregory K, Grose K, Monson S, **Varadarajan I**, **Volodin L**, Donowitz GR, Kindwall-Keller TL, **Ballen KK**. *Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation*. Hematol Oncol Stem Cell Ther. 2023 Jan 12;16(1):61-69. doi: 10.1016/j.hemonc.2021.05.001. PMID: 36634280.

Varadarajan I, Pierce E, Scheuing L, Morris A, **El Chaer F**, **Keng M**. Post- Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions. Onco Targets Ther. 2023 Jan 14;16:1-16. doi: 10.2147/OTT.S274551. PMID: 36685611; PMCID: PMC9849790.

El Chaer F, Hourigan CS, Zeidan AM. *How I treat AML incorporating the updated classifications and guidelines*. Blood. 2023 Jun 8;141(23):2813-2823. doi: 10.1182/blood.2022017808. PMID: 36758209; PMCID: PMC10447497.

Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, **Ballen K**, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. *Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis*. Haematologica. 2023 Jul 1;108(7):1900-1908. doi: 10.3324/haematol.2022.281958. PMID: 36779595; PMCID: PMC10316233.

SELECT PUBLICATIONS

Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, **Portell CA**, Mejia Garcia A, Goldsmith S, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar O, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. *A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma*. Blood Adv. 2023 Jul 11;7(13):2983-2993. doi: 10.1182/bloodadvances.2022008916. PMID: 36809796; PMCID: PMC10320213.

Xie X, Shirasu T, Li J, Guo LW, Kent KC. *miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4*. Cell Death Discov. 2023 Feb 22;9(1):73. doi: 10.1038/s41420-023-01364-7. PMID: 36813774; PMCID: PMC9946956.

Kilmartin C, Westover C, Raghavan S, **Dillon PM**, Campbell CA. *Desmoid Tumor and Implant-Based Breast Reconstruction*. Case Rep Oncol. 2023 Feb 14;16(1):74-80. doi: 10.1159/000525350. PMID: 36817360; PMCID: PMC9929649.

Sakae H, Ogiso Y, Matsuda M, Shimora H, Deering T, **Fox TE**, Kester M, Nabe T, Kitatani K. *Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma*. Cells. 2023 Feb 11;12(4):591. doi: 10.3390/cells12040591. PMID: 36831258; PMCID: PMC9954069.

Ward KA, Muller DA, Dutta SW, Malhi J, Sanders JC, Luminais CK, **Millard TA**, Showalter TN, Showalter SL, Janowski EM. *Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Early Stage Hormone Receptor Positive Breast Cancer*. Clin Breast Cancer. 2023 Jun;23(4):369-377. doi: 10.1016/j.clbc.2023.01.012. Epub 2023 Feb 1. PMID: 36868913.

Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, **El Chaer F**, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS. *DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant*. JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363. PMID: 36881031; PMCID: PMC9993183.

Jusino S, Fadul CE, **Dillon P**. *Systematic review of the management of brain metastases from hormone receptor positive breast cancer*. J Neurooncol. 2023 Mar;162(1):45-57. doi: 10.1007/s11060-023-04276-9. Epub 2023 Mar 8. PMID: 36884200; PMCID: PMC10049940.

Li J, Huang T, Hua J, Wang Q, Su Y, Chen P, Bidlingmaier S, Li A, Xie Z, Bidkar AP, Shen S, Shi W, Seo Y, Flavell RR, Gioeli D, **Dreicer R**, Li H, Liu B, He J. *CD46 targeted 212 Pb alpha particle radioimmunotherapy for prostate cancer treatment*. J Exp Clin Cancer Res. 2023 Mar 11;42(1):61. doi: 10.1186/s13046-023-02636-x. PMID: 36906664; PMCID: PMC10007843.

Fisher-Wellman KH, Kassai M, Hagen JT, Neuffer PD, Kester M, **Loughran TP Jr**, **Chalfant CE**, **Feith DJ**, **Tan SF**, **Fox TE**, Ung J, Fabrias G, Abad JL, Sharma A, Golla U, Claxton DF, Shaw JJP, Bhowmick D, Cabot MC. *Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia*. Cancers (Basel). 2023 Mar 21;15(6):1883. doi: 10.3390/cancers15061883. PMID: 36980769; PMCID: PMC10046858.

Thim EA, **Fox T**, Deering T, Vass LR, Sheybani ND, Kester M, Price RJ. *Solid Tumor Treatment via Augmentation of Bioactive C6 Ceramide Levels with Thermally Ablative Focused Ultrasound*. bioRxiv [Preprint]. 2023 Mar 23:2023.03.23.532394. doi: 10.1101/2023.03.23.532394 Update in: Drug Deliv Transl Res. 2023 Jun 19;: PMID: 36993445; PMCID: PMC10055354.

Kaur V, Rooney A, Horton BJ. *Prognostic significance of extra-nodal extension and positive surgical margins in HPV positive oropharyngeal squamous cell carcinoma*. Am J Otolaryngol. 2023 Jul-Aug;44(4):103877. doi: 10.1016/j.amjoto.2023.103877. Epub 2023 Mar 31. PMID: 37030131.

Wei CX, Mamdani H, **Gentzler R**, Kalra M, Perkins S, Althouse S, Jalal SI. *A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer*. Clin Lung Cancer. 2023 Jun;24(4):347-352. doi: 10.1016/j.clcc.2023.03.003. Epub 2023 Mar 21. PMID: 37032265.

Rogers CB, Kram RE, Lin K, Myers CL, Sobeck A, **Hendrickson EA**, Bielinsky AK. *Fanconi anemia-associated chromosomal radial formation is dependent on POLθ-mediated alternative end joining*. Cell Rep. 2023 May 30;42(5):112428. doi: 10.1016/j.celrep.2023.112428. Epub 2023 Apr 21. PMID: 37086407; PMCID: PMC10321316.

Lowrance W, **Dreicer R**, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC, Cookson MS. *Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)*. J Urol. 2023 Jun;209(6):1082-1090. doi: 10.1097/JU.0000000000003452. Epub 2023 Apr 25. PMID: 37096583.

Stephenson DJ, MacKnight HP, Hoeflerlin LA, Washington SL, Sawyers C, Archer KJ, Strauss JF 3rd, Walsh SW, **Chalfant CE**. *Bioactive lipid mediators in plasma are predictors of preeclampsia irrespective of aspirin therapy*. J Lipid Res. 2023 Jun;64(6):100377. doi: 10.1016/j.jlr.2023.100377. Epub 2023 Apr 27. PMID: 37119922; PMCID: PMC10230265.

Ma H, **Loughran TP Jr**, Gupta P. *An analysis of veterans diagnosed with large granular lymphocytic disorders at the national Veteran Affairs Healthcare System*. Am J Hematol. 2023 Aug;98(8):E190-E192. doi: 10.1002/ajh.26948. Epub 2023 May 4. PMID: 37139908.

Jayappa KD, Tran B, Gordon VL, Morris C, Saha S, Farrington CC, **O'Connor CM**, Zawacki KP, Isaac KM, Kester M, Bender TP, **Williams ME**, **Portell CA**, Weber MJ, Narla G. *PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis*. J Clin Invest. 2023 Jul 3;133(13):e155938. doi: 10.1172/JCI155938. PMID: 37166997; PMCID: PMC10313372.

Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ. *High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study*. Blood Adv. 2023 Nov 14;7(21):6381-6394. doi: 10.1182/bloodadvances.2023009731. PMID: 37171397; PMCID: PMC10598493.

DIVISION OF HEMATOLOGY & ONCOLOGY

SELECT PUBLICATIONS

Lantz J, Portell CA, Ayers EC. *Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?* Blood Rev. 2023 Sep;61:101101. doi: 10.1016/j.blre.2023.101101. Epub 2023 May 26. PMID: 37258362.

Brammer JE, Ballen K, Sokol L, Querfeld C, Nakamura R, Mishra A, McLaughlin EM, Feith D, Azimi N, Waldmann TA, Tagaya Y, Loughran T. *Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia.* Blood. 2023 Oct 12;142(15):1271-1280. doi: 10.1182/blood.2022017643. PMID: 37352612; PMCID: PMC10613725.

Mort JF, Tran DT, Dougherty SC, Zielinski R, Williams MD, Davidson KM. *Refractory Immune Thrombocytopenic Purpura with Abdominal Splenosis: A Complex Case.* Case Rep Hematol. 2023 Jun 21;2023:9714457. doi: 10.1155/2023/9714457. PMID: 37388486; PMCID: PMC10307128.

Rapaport F, Seier K, Neelamraju Y, Hassane D, Baslan T, Gildea DT, Haddox S, Lee T, Murdock HM, Sheridan C, Thurmond A, Wang L, Carroll M, Cripe LD, Fernandez H, Mason CE, Paietta E, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Gönen M, Levine R, Melnick AM, Kleppe M, Garrett-Bakelman FE. *Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.* Blood Cancer J. 2023 Jul 6;13(1):103. doi: 10.1038/s41408-023-00862-2. Erratum for: Blood Cancer J. 2022 Sep 23;12(9):137. PMID: 37407550; PMCID: PMC10322919.

Rencsok EM, Slopen N, Autio K, Morgans A, McSwain L, Barata P, Cheng HH, Dreicer R, Heath E, McKay RR, Pomerantz M, Rathkopf D, Tagawa S, Whang YE, Ragin C, Odedina FT, George DJ, Kantoff PW, Vinson J, Villanti P, Haneuse S, Mucci LA; IRONMAN Registry. *Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.* Qual Life Res. 2023 Nov;32(11):3209-3221. doi: 10.1007/s11136-023-03468-0. Epub 2023 Jul 6. PMID: 37410340; PMCID: PMC10711502.

Maus KD, Stephenson DJ, Macknight HP, Vu NT, Hoeflerlin LA, Kim M, Diegelmann RF, Xie X, Chalfant CE. *Skewing cPLA2 α activity toward oxoecosanoid production promotes neutrophil N2 polarization, wound healing, and the response to sepsis.* Sci Signal. 2023 Jul 11;16(793):eadd6527. doi: 10.1126/scisignal.add6527. Epub 2023 Jul 11. PMID: 37433004; PMCID: PMC10565596.

Ayers E, Canderan G, Williams ME, Keshavarz B, Portell CA, Wilson JM, Woodfolk JA. *In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms.* Blood Cancer J. 2023 Jul 26;13(1):114. doi: 10.1038/s41408-023-00884-w. PMID: 37495573; PMCID: PMC10372059.

Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Zucenka A, Zeidan AM. *Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.* Lancet Haematol. 2023 Sep;10(9):e767-e776. doi: 10.1016/S2352-3026(23)00159-X. Epub 2023 Aug 9. PMID: 37572683.

Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierito PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrer G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. *Systemic Therapy for Melanoma: ASCO Guideline Update.* J Clin Oncol. 2023 Oct 20;41(30):4794-4820. doi: 10.1200/JCO.23.01136. Epub 2023 Aug 14. PMID: 37579248.

Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. *Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.* Blood Adv. 2023 Nov 14;7(21):6630-6638. doi: 10.1182/bloodadvances.2023010622. PMID: 37595053; PMCID: PMC10628810.

Haque TT, Taruselli MT, Kee SA, Dailey JM, Pondicherry N, Gajewski-Kurziel PA, Zellner MP, Stephenson DJ, MacKnight HP, Straus DB, Kankaria R, Jackson KG, Chumanovich AP, Fukuoka Y, Schwartz LB, Blakely RD, Oskertizian CA, Chalfant CE, Martin RK, Ryan JJ. *Fluoxetine restrains allergic inflammation by targeting an Fc ϵ RI-ATP positive feedback loop in mast cells.* Sci Signal. 2023 Sep 12;16(802):eabc9089. doi: 10.1126/scisignal.abc9089. Epub 2023 Sep 12. PMID: 37699080; PMCID: PMC10759315.

Lucchesi N, Ally JM, Reilley MJ. *Complete response to immunotherapy in a patient with high-risk stage III colorectal cancer after ctDNA-guided detection of early adjuvant treatment failure.* J Immunother Cancer. 2023 Sep;11(9):e007434. doi: 10.1136/jitc-2023-007434. PMID: 37714563; PMCID: PMC10510882.

El Chaer F, Kaul DR, Englund JA, Boeckh M, Batista MV, Seo SK, Carpenter PA, Navarro D, Hirsch HH, Ison MG, Papanicolaou GA, Chemaly RF. *American Society of Transplantation and Cellular Therapy Series: #7 - Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.* Transplant Cell Ther. 2023 Dec;29(12):730-738. doi: 10.1016/j.jtct.2023.09.018. Epub 2023 Sep 30. PMID: 37783338.

Selesky M, Elghawy O, Kaur V. *Improved survival for stage IV sinonasal small cell neuroendocrine carcinoma treated with chemotherapy and anti-PD-L1 therapy.* BMJ Case Rep. 2023 Nov 17;16(11):e255313. doi: 10.1136/bcr-2023-255313. PMID: 37977842; PMCID: PMC10660969.

Schleffman J, Brenin C, Millard T, Dillon P. *Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy.* Med Oncol. 2023 Dec 16;41(1):19. doi: 10.1007/s12032-023-02255-8. PMID: 38103078.

Tandon M, Yacur M, Brenin C, Dillon P. *Cryotherapy for prevention of chemotherapy induced peripheral neuropathy in breast cancer.* Crit Rev Oncol Hematol. 2023 Dec 20;194:104244. doi: 10.1016/j.critrevonc.2023.104244. Epub ahead of print. PMID: 38135017.

Ung J, Tan SF, Fox TE, Shaw JJP, Taori M, Horton BJ, Golla U, Sharma A, Szulec ZM, Wang HG, Chalfant CE, Cabot MC, Claxton DF, Loughran TP Jr, Feith DJ. *Acid Ceramidase Inhibitor LCL-805 Antagonizes Akt Signaling and Promotes Iron-Dependent Cell Death in Acute Myeloid Leukemia.* Cancers (Basel). 2023 Dec 15;15(24):5866. doi: 10.3390/cancers15245866. PMID: 38136410; PMCID: PMC10742122.

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

Hematology/Oncology faculty serve as PIs on 120 active protocols.

BREAST

A Phase I/II Study of Anti-CD3xAnti-HER2/neu (HER2Bi) Armed Activated T Cells (ATC) and Pembrolizumab Combination Therapy in Women with Metastatic Breast Cancer

IRB # 19406

CT. Gov. ID: NCT03272334

Sponsor Protocol: Breast 47 BATs

Sponsor: University of Virginia

Principal Investigator: Dillon, Patrick

Study Contact: Ann Brown amb8e@uvahealth.org/Ashley

Donihee zwz6jm@uvahealth.org 434-243-6377

Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

IRB # HSR200069

CT. Gov. ID: NCT04090398

Sponsor Protocol: 10302

Sponsor: ETCTN

Principal Investigator: Dillon, Patrick

Study Contact: Olena Glushakova oyg2n@uvahealth.org

Focused Ultrasound and Low-Dose Gemcitabine to Augment Immune Control of Early Stage Breast Cancer

IRB # HSR200277

CT. Gov. ID: NCT04796220

Sponsor Protocol: BREAST54

Sponsor: University of Virginia

Principal Investigator: Dillon, Patrick

Study Contact: Ann Brown amb8e@uvahealth.org 434-243-9900

Cara Hanby clh5ke@virginia.edu 434-924-8709

Jay H Burchard jhb9r@uvahealth.org 434-924-0180

Kim A Bullock b9d@virginia.edu

A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

IRB # HSR220068

CT. Gov. ID: NCT05374512

Sponsor Protocol: TROPION-Breast02

Sponsor: AstraZeneca

Principal Investigator: Dillon, Patrick

Study Contact: Olena Glushakova oyg2n@uvahealth.org

Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy

IRB # HSR220088

CT. Gov. ID: NCT05068726

Sponsor Protocol: GE-280-401

Sponsor: GE Healthcare, Ltd

Principal Investigator: Brenin, Christiana

Study Contact: Linh-an Cao pbd2am@uvahealth.org 434-297-8785

BREAST

A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

IRB # HSR220277

CT. Gov. ID: NCT05467891

Sponsor Protocol: HCRN BRE20-468 / RaPhLRR

Sponsor: University of Illinois

Principal Investigator: Millard, Trish

Study Contact: Olena Glushakova oyg2n@uvahealth.org

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

IRB # HSR220393

CT. Gov. ID: NCT05514054

Sponsor Protocol: EMBER-4 / J2J-MC-JZLH

Sponsor: University of Illinois

Principal Investigator: Millard, Trish

Study Contact: Olena Glushakova oyg2n@uvahealth.org

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors

IRB # HSR2203977

CT. Gov. ID: NCT04925284

Sponsor Protocol: XB002-101

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Kate Skoczylas ks5jk@virginia.edu

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

IRB # HSR230088

CT. Gov. ID: NCT05633654

Sponsor Protocol: GS-US-595-6184 / ASCENT-05

Sponsor: Gilead Sciences, Inc.

Principal Investigator: Dillon, Patrick

Study Contact: Olena Glushakova oyg2n@uvahealth.org

CALM: Chronic & Acute Leukemia/MDS & MPN

A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

IRB # HSR200064

CT. Gov. ID: NCT04176198

Sponsor Protocol BBI-TP-3654-102

Sponsor: Sumitomo Pharma Oncology Inc.

Principal Investigator: El Chaer, Firas

Study Contact: Avani J Hopkins ajh7jqe@uvahealth.org 434-243-8108

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

CALM: Chronic & Acute Leukemia/MDS & MPN

Palliative Care Oncology in Relapsed, Refractory, and High-Risk Leukemia Patients: Randomized Phase II Study

IRB # HSR200133

CT. Gov. ID: NCT04482894

Sponsor Protocol: ALeuk 001

Sponsor: University of Virginia

Principal Investigator: El Chaer, Firas

Study Contact: Ann Brown amb8e@uvahealth.org 434-243-9900

Cara Hanby clh5ke@virginia.edu 434-924-7261

Emily Leytham el5mf@virginia.edu 434-924-8709

Jay H Burchard jhb9r@uvahealth.org 434-924-0180

Kim A Bullock kb9d@virginia.edu

A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission

IRB # HSR200142

CT. Gov. ID: NCT04506086

Sponsor Protocol: 20190014

Sponsor: Amgen

Principal Investigator: Keng, Michael

Study Contact: Cory Caldwell cjc2p@uvahealth.org 434-297-4182

Phase II Trial of Cardioprotective Prophylaxis with Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia

IRB # HSR210151

CT. Gov. ID: NCT04977180

Sponsor Protocol: BREAST54

Sponsor: University of Virginia

Principal Investigator: Keng, Michael

Study Contact: Ann Brown amb8e@uvahealth.org 434-243-9900

Cara Hanby clh5ke@virginia.edu 434-924-7261

Emily Leytham el5mf@virginia.edu 434-924-8709

Jay H Burchard jhb9r@uvahealth.org 434-924-0180

Kim A Bullock kb9d@virginia.edu 434-924-0180

A Pilot Trial Using Isatuximumab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients

IRB # HSR210463

CT. Gov. ID: NCT05284032

Sponsor Protocol: SuppCare 001

Sponsor: University of Virginia

Principal Investigator: El Chaer, Firas

Study Contact: Ann Brown amb8e@uvahealth.org 434-243-9900

Cara Hanby clh5ke@virginia.edu 434-924-7261

Emily Leytham el5mf@virginia.edu 434-924-8709

Jay H Burchard jhb9r@uvahealth.org 434-924-0180

Kim A Bullock kb9d@virginia.edu 434-924-0180

CALM: Chronic & Acute Leukemia/MDS & MPN

A Phase I/II Dose Escalation and Expansion Study of BST-236 plus Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Induction Chemotherapy

IRB # HSR220094

CT. Gov. ID: NCT05503355

Sponsor Protocol: BST005

Sponsor: BioSight Ltd.

Principal Investigator: Keng, Michael

Study Contact: Cory Caldwell cjc2p@uvahealth.org 434-297-4182

A Phase 1, Open-Label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia

IRB # HSR220292

CT. Gov. ID: NCT03547115

Sponsor Protocol: ME-522-001

Sponsor: MEI Pharma, Inc.

Principal Investigator: Keng, Michael

Study Contact: Cory Caldwell cjc2p@uvahealth.org 434-297-4182

A Phase IIIb, Single-Arm, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Ropoginterferon alfa-2b-njft (P1101) in Adult Patients with Polycythemia Vera (PV)

IRB # HSR220401

CT. Gov. ID: NCT05481151

Sponsor Protocol: A22-203

Sponsor: PharmaEssentia USA Corporation

Principal Investigator: El Chaer, Firas

Study Contact: Cory Caldwell cjc2p@uvahealth.org

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropoginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia

IRB # HSR230024

CT. Gov. ID: NCT05482971

Sponsor Protocol: A22-301

Sponsor: PharmaEssentia USA Corporation

Principal Investigator: El Chaer, Firas

Study Contact: Avani J Hopkins ajh7jqe@uvahealth.org 434-243-8108

Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 trial

IRB # HSR230204

CT. Gov. ID: NCT04176198

Sponsor Protocol: 10538

Sponsor: ETCTN

Principal Investigator: Reed, Daniel

Study Contact: Cory Caldwell cjc2p@uvahealth.org

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

Cellular Therapies

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications

IRB # 15670

CT. Gov. ID: NCT01351545

Sponsor Protocol: 10-CBA Unlicensed CVU

Sponsor: National Marrow Donor Program (NMDP)

Principal Investigator: Ballen, Karen

Study Contact: Danyelle Coley jcs6rz@uvahealth.org 434-982-5027

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients

IRB # 16168

CT. Gov. ID: NCT01656603

Sponsor Protocol: 6637-01 NCBP Unlicensed CVU

Sponsor: National Cord Blood Program

Principal Investigator: Ballen, Karen

Study Contact: Danyelle Coley jcs6rz@uvahealth.org

A Phase I/II Study of Anti-CD3xAnti-HER2/neu (HER2Bi) Armed Activated T Cells (ATC) and Pembrolizumab Combination Therapy in Women with Metastatic Breast Cancer

IRB # 19406

CT. Gov. ID: NCT03272334

Sponsor Protocol: Breast 47 BATs

Sponsor: University of Virginia

Principal Investigator: Dillon, Patrick

Study Contact: Ann Brown amb8e@uvahealth.org
Ashley Donihee zwz6jm@uvahealth.org 434-243-6377

Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis

IRB # 19792

CT. Gov. ID: NCT02934477

Sponsor Protocol: 16-CMS-MF

Sponsor: Center for the International Blood and Marrow Transplant

Principal Investigator: Ballen, Karen

Study Contact: Emily Leytham el5mf@virginia.edu 434-924-7261

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)

IRB # 20533

CT. Gov. ID: NCT03127761

Sponsor Protocol: 17-CMS-MM

Sponsor: Center for the International Blood and Marrow Transplant

Principal Investigator: Volodin, Leonid

Study Contact: Emily Leytham el5mf@virginia.edu

Cellular Therapies

Assessment of Allogeneic Hematopoietic Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related disorders - Part I.

IRB # 20714

CT. Gov. ID:

Sponsor Protocol: 10-CMS-MDS

Sponsor: Center for the International Blood and Marrow Transplant

Principal Investigator: Varadarajan, Indumathy

Study Contact: Emily Leytham el5mf@virginia.edu 434-924-7261

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

IRB # 21445

CT. Gov. ID: NCT03601442

Sponsor Protocol: Kymriah_CCTL019B2003I

Sponsor: Novartis

Principal Investigator: Varadarajan, Indumathy

Study Contact: Danyelle Coley jcs6rz@uvahealth.org 434-982-5027

Long G-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T-Cells

IRB # HSR200219

CT. Gov. ID: NCT03435796

Sponsor Protocol: GC-LTFU-001

Sponsor: Celgene

Principal Investigator: Varadarajan, Indumathy

A multi-center, phase II trial of HLA-mismatched unrelated donor hematopoietic cell transplantation with post-transplantation cyclophosphamide for patients with hematologic malignancies

IRB # HSR210160

CT. Gov. ID: NCT04904588

Sponsor Protocol: ACCESS

Sponsor: National Marrow Donor Program (NMDP)

Principal Investigator: Ballen, Karen

Study Contact: Emily Leytham el5mf@virginia.edu 434-924-7261

Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients with CD 123+ Acute Myeloid Leukemia, Myelofibrosis and Chronic Myelomonocytic Leukemia

IRB # HSR210434

CT. Gov. ID: NCT05233618

Sponsor Protocol: HSR210434

Sponsor: University of Virginia

Principal Investigator: Ballen, Karen

Study Contact: Ann Brown amb8e@uvahealth.org

Cara Hanby clh5ke@virginia.edu 434-243-9900

Jay H Burchard jhb9r@uvahealth.org 434-924-8709

Kim A Bullock kb9d@virginia.edu 434-924-0180

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

Cellular Therapies

A Phase 2/3, Multicenter, randomized, Double-blind, placebo-controlled, study to evaluate the safety and efficacy of Alpha-1 Antitrypsin for the prevention of graft-versus host disease in patients receiving hematopoietic cell transplant (MODULAATE Study)

IRB # 15670

CT. Gov. ID: NCT03805789

Sponsor Protocol: CSL964_2001

Sponsor: CSL Behring, LLC

Principal Investigator: Volodin, Leonid

Study Contact: Danyelle Coley jcs6rz@uvahealth.org
434-982-5027

A phase 3 randomized study comparing bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacebtogene autoleucel, a chimeric antigen receptor T cell (CAR-T) Therapy directed against CMA versus bortezomib, lenalidomide, and dexamethasone (VRd) followed by lenalidomide and dexamethasone (RD therapy in patients with newly diagnosed multiple myeloma for who hematopoietic stem cell transplant is not planned as initial therapy

IRB # 16168

CT. Gov. ID: NCT04923893

Sponsor Protocol: 68284528MMY3004

Sponsor: Janssen Research & Development

Principal Investigator: Foster, Laahn

Study Contact: Sara Casana Granell qna7wg@uvahealth.org
434-924-5254

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

IRB # HSR230345

CT. Gov. ID: NCT06001385

Sponsor Protocol: OPTIMIZE

Sponsor: Center for the International Blood and Marrow Transplant

Principal Investigator: Ballen, Karen

Study Contact: Eva Forman stw7ak@uvahealth.org

Single Patient Expanded Access TA-TMA

CT. Gov. ID: NCT02934477

Sponsor Protocol: NARSOPLIMAB sIND

Sponsor: Omeros Corporation

Principal Investigator: Varadarajan, Indumathy

Study Contact: Danyelle Coley jcs6rz@uvahealth.org

Developmental Therapeutics

A phase 1b/2, master protocol evaluating the safety, tolerability, pharmacokinetics, and efficacy of sotarasib (AMG 510) in subjects with advanced solid tumors with KRAS p.G12C Mutation

IRB # HSR220237

CT. Gov. ID: NCT04185883

Sponsor Protocol: 20190135

Sponsor: Amgen

Principal Investigator: Gentzler, Ryan

Study Contact: Lacey N Garrett lb5tu@uvahealth.org
434-297-5588

Developmental Therapeutics

A phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with MGD019 in participants with advanced solid tumors

IRB # HSR220272

CT. Gov. ID: NCT05293496

Sponsor Protocol: CP-MGC018-02

Sponsor: MacroGenics, Inc.

Principal Investigator: Reilley, Matthew

Study Contact: Francis Bagley fb9up@uvahealth.org

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors

IRB # HSR220397

CT. Gov. ID: NCT04925284

Sponsor Protocol: XB002-101

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Kate Skoczylas ks5jk@virginia.edu

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

IRB # HSR230073

CT. Gov. ID: NCT05225584

Sponsor Protocol: Kymera Therapeutics, Inc.

Sponsor: Celgene

Principal Investigator: Marchi, Enrica

Study Contact: DeJuana Coleman evq9yw@uvahealth.org
434-924-9199

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

IRB # HSR230092

CT. Gov. ID: NCT05176483

Sponsor Protocol: XL092-002 / STELLAR-002

Sponsor: EXELIXIS, Inc

Principal Investigator: Dreicer, Robert

Study Contact: Alexandra Cash aec5gn@uvahealth.org
434-243-4305

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors

IRB # HSR230149

CT. Gov. ID: NCT04249843

Sponsor Protocol: BGB-3245-AU-001

Sponsor: MapKure, LLC

Principal Investigator: Gaughan, Elizabeth

Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

Developmental Therapeutics

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors

IRB # HSR230149

CT. Gov. ID: NCT04249843

Sponsor Protocol: BGB-3245-AU-001

Sponsor: MapKure, LLC

Principal Investigator: Gaughan, Elizabeth

Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

Gastro-intestinal (GI)

A phase 1b/2, master protocol evaluating the safety, tolerability, pharmacokinetics, and efficacy of sotarasib (AMG 510) in subjects with advanced solid tumors with KRAS p.G12C Mutation

IRB # HSR220237

CT. Gov. ID: NCT04185883

Sponsor Protocol: 20190135

Sponsor: Amgen

Principal Investigator: Gentzler, Ryan

Study Contact: Lacey N Garrett lb5tu@uvahealth.org
434-297-5588

A phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with MGD019 in participants with advanced solid tumors

IRB # HSR22027

CT. Gov. ID: NCT05293496

Sponsor Protocol: CP-MGC018-02

Sponsor: MacroGenics, Inc.

Principal Investigator: Reilley, Matthew

Study Contact: Francis Bagley fb9up@uvahealth.org

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors

IRB # HSR220397

CT. Gov. ID: NCT04925284

Sponsor Protocol: XB002-101

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Kate Skoczylas ks5jk@virginia.edu

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

IRB # HSR230092

CT. Gov. ID: NCT05176483

Sponsor Protocol: XL092-002 / STELLAR-002

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Alexandra Cash aec5gn@uvahealth.org
434-243-4305

Gastro-intestinal (GI)

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors

IRB # HSR230149

CT. Gov. ID: NCT04249843

Sponsor Protocol: BGB-3245-AU-001

Sponsor: MapKure, LLC

Principal Investigator: Gaughan, Elizabeth

Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy-and FGFR Inhibitor Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

IRB # HSR230329

CT. Gov. ID: NCT05948475

Sponsor Protocol: TT420C2308 / FIRST-308

Sponsor: TransThera Sciences (Nanjing), Inc.

Principal Investigator: Kunk, Paul

Study Contact: Kristen A Harris kah2gv@uvahealth.org
434-297-5724

GenitoUrinary (GU)

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)

IRB # 19690

CT. Gov. ID: NCT03151629

Sponsor Protocol: c16-170

Sponsor: Cancer Clinical Trials Consortium, LLC

Principal Investigator: Dreicer, Robert

Study Contact: Emily Leytham el5mf@virginia.edu
434-924-7261

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair

IRB # 21826

CT. Gov. ID: NCT04019327

Sponsor Protocol: C18-205

Sponsor: Memorial Sloan-Kettering Cancer Center

Principal Investigator: Devitt, Michael

Study Contact: Christine Martin cmp2p@uvahealth.org

A Phase II Open-Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy

IRB # HSR210450

CT. Gov. ID: NCT03547973

Sponsor Protocol: IMMU-132-06

Sponsor: Gilead Sciences, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Christine Martin cmp2p@uvahealth.org

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

Gastro-intestinal (GI)

A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients with Metastatic Castration-Resistant Prostate Cancer

IRB # HSR220253

CT. Gov. ID: NCT05067140

Sponsor Protocol: ARV-766-mCRPC-101

Sponsor: Arvinas, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Jasmine Lu jl2bw@uvahealth.org

A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination with Palbociclib (Doublet) and with Palbociclib and Sasanlimab (Triplet) in Patients with Advanced or Metastatic Renal Clear Cell Carcinoma

IRB # HSR220311

CT. Gov. ID: NCT05935748

Sponsor Protocol: NKT2152-202

Sponsor: NiKang Therapeutics, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Steven H Goff wrs9hw@uvahealth.org

434-297-4126

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors

IRB # HSR220397

CT. Gov. ID: NCT04925284

Sponsor Protocol: XB002-101

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Kate Skoczylas ks5jk@virginia.edu

A phase II multicenter study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma that progressed on a PD-1/PD-L1 checkpoint inhibitor. Acronym: LenCabo

IRB # HSR220466

CT. Gov. ID: NCT05012371

Sponsor Protocol: 2021-0400

Sponsor: MD Anderson CC

Principal Investigator: Skelton, William

Study Contact: Christine Martin cmp2p@uvahealth.org

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

IRB # HSR230092

CT. Gov. ID: NCT05176483

Sponsor Protocol: XL092-002 / STELLAR-002

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Alexandra Cash aec5gn@uvahealth.org

434-243-4305

Gastro-intestinal (GI)

A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer

IRB # HSR230238

CT. Gov. ID: NCT05848011

Sponsor Protocol: CP-MGD019-02

Sponsor: MacroGenics, Inc

Principal Investigator: Skelton, William

Study Contact: Christine Martin cmp2p@uvahealth.org

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors

IRB # HSR22039

CT. Gov. ID: NCT04925284

Sponsor Protocol: XB002-101

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Kate Skoczylas ks5jk@virginia.edu

Head & Neck

Phase 1-2 study investigating safety, tolerability, pharmacokinetics and preliminary antitumor activity of anti-TIM-3-Monoclonal antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in patients with advanced solid tumors

IRB # HSR220014

CT. Gov. ID: NCT03744468

Sponsor Protocol: BGB-900-102

Sponsor: BeiGene, Ltd.

Principal Investigator: Kaur, Varinder

Study Contact: Olusegun Adelaja oba4e@uvahealth.org

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

IRB # HSR230092

CT. Gov. ID: NCT05176483

Sponsor Protocol: XL092-002 / STELLAR-002

Sponsor: EXELIXIS, Inc

Principal Investigator: Dreicer, Robert

Study Contact: Alexandra Cash aec5gn@uvahealth.org

434-243-4305

A Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer

IRB # HSR220202

CT. Gov. ID: NCT05172245

Sponsor Protocol: 10492

Sponsor: ETCTN

Principal Investigator: Kaur, Varinder

Study Contact: Olusegun Adelaja oba4e@uvahealth.org

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

Head & Neck

A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination with INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants with PD-L1-Positive (CPS ≥ 1) Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

IRB # HSR220252

CT. Gov. ID: NCT05287113

Sponsor Protocol: INCAGN 2385-203

Sponsor: Incyte Corporation

Principal Investigator: Kaur, Varinder

Study Contact: Zoe Hemmer zh7jf@virginia.edu

A Phase I/III Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

IRB # HSR220352

CT. Gov. ID: NCT04180215

Sponsor Protocol: H-200-001

Sponsor: Hookipa Biotech GmbH

Principal Investigator: Kaur, Varinder

Study Contact: Olusegun Adelaja oba4e@uvahealth.org

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors

IRB # HSR220397

CT. Gov. ID: NCT04925284

Sponsor Protocol: XB002-101

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Kate Skoczylas ks5jk@virginia.edu

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

IRB # HSR230092

CT. Gov. ID: NCT05176483

Sponsor XL092-002 / STELLAR-002

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Alexandra Cash aec5gn@uvahealth.org
434-243-4305

Lymphoma

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

IRB # 20317

CT. Gov. ID: NCT03267433

Sponsor Protocol: EA4151

Sponsor: ECOG

Principal Investigator: Portell, Craig

Study Contact: Erica Stallard elg9r@uvahealth.org
434-243-2649

Lymphoma

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

IRB # HSR210225

CT. Gov. ID: NCT04799275

Sponsor Protocol: S1918

Sponsor: SWOG

Principal Investigator: Ayers, Emily

Study Contact: Study Contact: Erica Stallard elg9r@uvahealth.org 434-243-2649

A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy-and FGFR Inhibitor Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

IRB # HSR230329

CT. Gov. ID: NCT05948475

Sponsor Protocol: TT420C2308 / FIRST-308

Sponsor: TransThera Sciences (Nanjing), Inc.

Principal Investigator: Kunk, Paul

Study Contact: Kristen A Harris kah2gv@uvahealth.org

A phase Ib open-label study to evaluate the safety and anti-cancer activity of loncastuximab terisine in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

IRB # HSR220009

CT. Gov. ID: NCT04970901

Sponsor Protocol: ADCT-402-105

Sponsor: ADC Therapeutics S.A.

Principal Investigator: Ayers, Emily

Study Contact: Michal Ande mma2cz@uvahealth.org

MAJIC: A Phase III Prospective, Multicenter, Randomized, Open- Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

IRB # HSR220204

CT. Gov. ID: NCT03547973

Sponsor Protocol: D8220C00027

Sponsor: AstraZeneca

Principal Investigator: Portell, Craig

Study Contact: Michal Ande mma2cz@uvahealth.org

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

IRB # HSR220402

CT. Gov. ID: NCT04965493

Sponsor Protocol: LOXO-BTK-20022 (J2N-OX-JZ)

Sponsor: Eli Lilly

Principal Investigator: Ayers, Emily

Study Contact: Naomi Spencer jre8qk@uvahealth.org ④

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

Lymphoma

Pembrolizumab-based adaptive therapy for classical Hodgkin lymphoma in patients age 60 and above

IRB # HSR210534

CT. Gov. ID: NCT05404945

Sponsor Protocol: CHL001

Sponsor: University of Virginia

Principal Investigator: Portell, Craig

Study Contact: Ann Brown amb8e@uvahealth.org

Cara Hanby clh5ke@virginia.edu

Jay H Burchard jhb9r@uvahealth.org

Jennifer L Garth jlg8tg@uvahealth.org

Kim A Bullock kb9d@virginia.edu

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)

IRB # HSR220487

CT. Gov. ID: NCT04662255

Sponsor Protocol: LOXO-BTK-20019

Sponsor: Eli Lilly

Principal Investigator: Portell, Craig

Study Contact: Erica Stallard elg9r@uvahealth.org

434-243-2649

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma

IRB # 21772

CT. Gov. ID: NCT03969004

Sponsor Protocol: R2810-ONC-1788

Sponsor: Regeneron Pharmaceuticals, Inc.

Principal Investigator: Kaur, Varinder

Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study

IRB # HSR210158

CT. Gov. ID: NCT04708418

Sponsor Protocol: EA6194

Sponsor: ECOG-ACRIN

Principal Investigator: Gaughan, Elizabeth

Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-Risk Melanoma

IRB # HSR220467

CT. Gov. ID: NCT05608291

Sponsor Protocol: R3767-ONC-2055

Sponsor: Regeneron Pharmaceuticals, Inc.

Principal Investigator: Gaughan, Elizabeth

Study Contact: Rachael L Zhang rlz4fp@virginia.edu

571-699-6379

Lymphoma

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors

IRB # HSR230149

CT. Gov. ID: NCT04249843

Sponsor Protocol: BGB-3245-AU-001

Sponsor: MapKure, LLC

Principal Investigator: Gaughan, Elizabeth

Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

PBT: Plasma/Benign/T-Cell

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)

IRB # HSR200080

CT. Gov. ID: NCT04747236

Sponsor Protocol: PTCL-001

Sponsor: University of Virginia

Principal Investigator: Marchi, Enrica

Study Contact: Aishling Rada jdp5pg@uvahealth.org

434-924-0816

Ann Brown amb8e@uvahealth.org

Cara Hanby clh5ke@virginia.edu 434-243-9900

Jay H Burchard jhb9r@uvahealth.org 434-924-8709

Kim A Bullock kb9d@virginia.edu 434-924-0180

Novel immuno-epigenetic based platform for patients with peripheral T-cell Lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL): an international phase Ib study of pembrolizumab combined with decitabine and/or pralatrexate

IRB # HSR200265

CT. Gov. ID: NCT03240211

Sponsor Protocol: Not specified

Sponsor: University of Virginia

Principal Investigator: Marchi, Enrica

Study Contact: Aishling Rada jdp5pg@uvahealth.org

434-924-0816

Ann Brown amb8e@uvahealth.org

Cara Hanby clh5ke@virginia.edu 434-243-9900

Jay H Burchard jhb9r@uvahealth.org 434-924-8709

Kim A Bullock kb9d@virginia.edu 434-924-0180

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation

IRB # HSR210057

CT. Gov. ID: NCT04566328

Sponsor Protocol: EAA181

Sponsor: ECOG-ACRIN

Principal Investigator: Foster, Laahn

Study Contact: Aishling Rada jdp5pg@uvahealth.org

434-924-0816

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

PBT: Plasma/Benign/T-Cell

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

IRB # HSR200035

CT. Gov. ID: NCT03937635

Sponsor Protocol: EAA173

Sponsor: ECOG-ACRIN

Principal Investigator: Foster, Laahn

Study Contact: Aishling Rada jdp5pg@uvahealth.org
434-924-0816

A phase 3 randomized study comparing bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacebtogene autoleucel, a chimeric antigen receptor T cell (CAR-T) Therapy directed against CMA versus bortezomib, lenalidomide, and dexamethasone (VRd) followed by lenalidomide and dexamethasone (RD therapy in patients with newly diagnosed multiple myeloma for who hematopoietic stem cell transplant is not planned as initial therapy

IRB # HSR220093

CT. Gov. ID: NCT04923893

Sponsor Protocol: 68284528MMY3004

Sponsor: Janssen Research & Development

Principal Investigator: Foster, Laahn

Study Contact: Sara Casana Granell qna7wg@uvahealth.org
434-924-5254

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

IRB # HSR220315

CT. Gov. ID: NCT05475925

Sponsor Protocol: DR-01-ONC-001

Sponsor: Dren Bio, Inc

Principal Investigator: Marchi, Enrica

Study Contact: Aishling Rada jdp5pg@uvahealth.org

A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis

IRB # HSR220316

CT. Gov. ID: NCT04847453

Sponsor Protocol: 10440

Sponsor: ETCTN

Principal Investigator: Foster, Laahn

Study Contact: Alexandra Cash aec5gn@uvahealth.org
434-243-4305

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

IRB # HSR230073

CT. Gov. ID: NCT05225584

Sponsor Protocol: KT333-TL-101

Sponsor: Kymera Therapeutics, Inc.

Principal Investigator: Marchi, Enrica

Study Contact: DeJuana Coleman evq9yw@uvahealth.org
434-924-9199

PBT: Plasma/Benign/T-Cell

A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

IRB # HSR230148

CT. Gov. ID: NCT05455320

Sponsor Protocol: 64407564MMY3002

Sponsor: Janssen Research & Development

Principal Investigator: Foster, Laahn

Study Contact: Theresa Leak tol3w@uvahealth.org
434-243-4308

Thoracic

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

IRB # 17719

CT. Gov. ID: NCT02194738

Sponsor Protocol: A151216

Sponsor: ECOG-ACRIN

Principal Investigator: Hall, Richard

Study Contact: Lacey N Garrett lb5tu@uvahealth.org
434-297-5588

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

IRB # 17721

CT. Gov. ID: NCT02201992

Sponsor Protocol: E4512

Sponsor: ECOG-ACRIN

Principal Investigator: Hall, Richard

Study Contact: Gracie Hockenberry mgt4n@virginia.edu
434-297-7784

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

IRB # HSR220009

CT. Gov. ID: NCT03191149

Sponsor Protocol: EA5162

Sponsor: ECOG-ACRIN

Principal Investigator: Hall, Richard

Study Contact: Gracie Hockenberry mgt4n@virginia.edu
434-297-7784

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

IRB # HSR200034

CT. Gov. ID: NCT03909334

Sponsor Protocol: LUN18-335

Sponsor: MD Anderson CC

Principal Investigator: Hall, Richard

Study Contact: Gracie Hockenberry mgt4n@virginia.edu
Lacey N Garrett lb5tu@uvahealth.org 434-297-5588

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

Thoracic

ETCTN10216: A Phase I/II Study of AZD9291 and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer

IRB # HSR200081

CT. Gov. ID: NCT03831932

Sponsor Protocol: ETCTN10216

Sponsor: ETCTN

Principal Investigator: Hall, Richard

Study Contact: Lacey N Garrett lb5tu@uvahealth.org

434-297-5588

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

IRB # HSR200159

CT. Gov. ID: NCT04092283

Sponsor Protocol: EA5181

Sponsor: ECOG-ACRIN

Principal Investigator: Hall, Richard

Study Contact: Yaroslav Shvorak ys7cb@uvahealth.org

434-297-7384

A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm

IRB # HSR200297

CT. Gov. ID: NCT04317534

Sponsor Protocol: LUN18-153

Sponsor: Big Ten Cancer Research Consortium

Principal Investigator: Hall, Richard

Study Contact: Gracie Hockenberry mgt4n@virginia.edu

434-297-7784

A phase II study of adjuvant treatment with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors= 4cm), IIA, IIB, and select stage III [any T1-3, N1-2, and T4N0-2] resected non-small cell lung cancer (NSCLC) and the clearance of circulating tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396

IRB # HSR210517

CT. Gov. ID: NCT04367311

Sponsor Protocol: BTCRC-LUN19-396

Sponsor: Big Ten Cancer Research Consortium

Principal Investigator: Hall, Richard

Study Contact: Gracie Hockenberry mgt4n@virginia.edu

434-297-7784

A phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer

IRB # HSR230051

CT. Gov. ID: NCT05617313

Sponsor Protocol: LUN21-497

Sponsor: Hoosier Cancer Research Network

Principal Investigator: Gentzler, Ryan

Study Contact: Gracie Hockenberry mgt4n@virginia.edu

434-297-7784

Thoracic

A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9)

IRB # HSR220031

CT. Gov. ID: NCT05221840

Sponsor Protocol: D9078C00001

Sponsor: AstraZeneca

Principal Investigator: Gentzler, Ryan

Study Contact: Gracie Hockenberry mgt4n@virginia.edu

434-297-7784

A phase 3, randomized, double-blind study of MK-7684A in combination with etoposide and platinum followed by MK-7684A vs. atezolizumab in combination with etoposide and platinum followed by atezolizumab for the first-line treatment of participants with extensive- stage small cell lung cancer

IRB # HSR220218

CT. Gov. ID: NCT05224141

Sponsor Protocol: 008-01

Sponsor: Merck Sharp & Dohme Corp.

Principal Investigator: Hall, Richard

Study Contact: Gracie Hockenberry mgt4n@virginia.edu

A phase 1b/2, master protocol evaluating the safety, tolerability, pharmacokinetics, and efficacy of sotarasib (AMG 510) in subjects with advanced solid tumors with KRAS p.G12C Mutation

IRB # HSR220237

CT. Gov. ID: NCT04185883

Sponsor Protocol: 20190135

Sponsor: Amgen

Principal Investigator: Gentzler, Ryan

Study Contact: Lacey Garrett lb5tu@uvahealth.org 434-

297-5588

A Phase I, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors

IRB # HSR220309

CT. Gov. ID: NCT04511845

Sponsor Protocol: SPK101JG

Sponsor: Chugai Biopharmaceuticals

Principal Investigator: Gentzler, Ryan

Study Contact: Gracie Hockenberry mgt4n@virginia.edu

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors

IRB # HSR220397

CT. Gov. ID: NCT04925284

Sponsor Protocol: XB002-101

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Kate Skoczylas ks5jk@virginia.edu

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials

Thoracic

A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

IRB # HSR230066

CT. Gov. ID: NCT03831932

Sponsor Protocol: DZ2022E0005

Sponsor: Dizal Pharmaceutical Co., Ltd

Principal Investigator: Gentzler, Ryan

Study Contact: Gracie Hockenberry mgt4n@virginia.edu
434-297-7784

PRAGMATICA - LUNG: A Prospective Randomized Study of ramucirumab (LY3009806; NSC 749128) plus pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

IRB # HSR230068

CT. Gov. ID: NCT05633602

Sponsor Protocol: S2302

Sponsor: SWOG

Principal Investigator: Gentzler, Ryan

Study Contact: Gracie Hockenberry mgt4n@virginia.edu
434-297-7784

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

IRB # HSR230092

CT. Gov. ID: NCT05176483

Sponsor Protocol: XL092-002 / STELLAR-002

Sponsor: EXELIXIS, Inc.

Principal Investigator: Dreicer, Robert

Study Contact: Alexandra Cash aec5gn@uvahealth.org
434-243-4305

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors

IRB # HSR230149

CT. Gov. ID: NCT04249843

Sponsor Protocol: BGB-3245-AU-001

Sponsor: MapKure, LLC

Principal Investigator: Gaughan, Elizabeth

Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Cell Lung Cancer

IRB # HSR230339

CT. Gov. ID: NCT06095505

Sponsor Protocol: PUMA-ALI-4201

Sponsor: Puma Biotechnology, Inc.

Principal Investigator: Gentzler, Ryan

Study Contact: Gracie Hockenberry mgt4n@virginia.edu

Thoracic

A randomized, double-blind phase 2/3 study of Fianlimab (anti-lag 3 antibody), Cemiplimab (anti-pd-1 antibody), and chemotherapy versus cemiplimab and chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression levels.

IRB # HSR230219

CT. Gov. ID: NCT05800015

Sponsor Protocol: R3767-ONC-2236

Sponsor: Regeneron Pharmaceuticals, Inc.

Principal Investigator: Hall, Richard

Study Contact: Lacey N Garrett lb5tu@uvahealth.org
434-297-5588

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 >50%

IRB # HSR230214

CT. Gov. ID: NCT05785767

Sponsor Protocol: R3767-ONC-2235

Sponsor: Regeneron Pharmaceuticals, Inc.

Principal Investigator: Hall, Richard

Study Contact: Lacey N Garrett lb5tu@uvahealth.org
434-297-5588

Administration News



Nazif Maqani joined Hematology/Oncology on October 9, 2023, as the Senior Finance Generalist. Nazif has worked for the University of Virginia for 21 years, and we are delighted that Nazif has joined our team.

DIVISION OF HEMATOLOGY & ONCOLOGY

RESEARCH FACULTY PROFILE - Anuradha Illendula



Murali Illendula, my Husband

Tell us a little bit about yourself.

I have been at UVA for almost 18 years. I started my career at the University of Virginia as a Research Associate in Molecular Biology and Biological Physics, and my research focus was Protein-Protein Interaction inhibitor development for “undruggable” transcription factors in hematological cancers, specifically inv (16) AML. Before moving to the USA for postdoctoral experience, I gained comprehensive expertise that is critical for small molecule drug development, Organic synthesis of “Heterocyclic” molecules (Ph.D.), “combinatorial and parallel synthesis” (Postdoctoral), and Scale-up (industrial experience). My lab and I currently focus on developing drug delivery nanotechnologies and solutions to molecular (siRNA, mRNAs) and pharmaceutical (small molecules) to improve pharmacokinetics, bioavailability, and toxicological profiles through targeted delivery, precisely epigenetic modulating drugs. In addition, we also “re-formulate” oncological, immunological, neurological, and metabolic drugs to increase and extend IP protection.

Why Research?

Research, especially basic science research, is fundamental to developing healthcare solutions that touch everyone’s lives and improve quality of life. I have always been interested in healthcare and wanted to contribute my efforts toward work that benefits the most people.

What brought you to Charlottesville?

My employment brought me to Charlottesville. My passion for drug development and UVA resources in multidisciplinary academic research entrepreneurship, from innovation to impact, is a foundation for my long-term stay.

What excites you about your work?

Finding new treatments/medicines is hitting a target in the dark. The journey of novel drug discovery is arduous and requires excellent teamwork, perseverance, hard work, and dedication. The payoff of developing a new treatment is exhilarating and beneficial to all.

What do you consider to be your greatest achievement outside the professional realm?

Despite being thousands of miles away, I try to stay connected with my family and offer my support to be together. Family is a smaller version of society and is the most vital part of life. I am grateful to have a loving and supportive one.

Describe yourself in one word.

Resilient.



Neela (Neelaambari), Our Pet

What do you enjoy doing on the weekend?

My parents and spiritual teacher highly motivated me to teach values, gratitude, humility, and responsibility from childhood while acquiring technical skills that significantly impact a child’s personality development. I serve the community by providing a support system to train kids to gain these moral values and put that knowledge into action to make them outstanding citizens.

How did you meet your partner?

I met my husband, Murali Illendula, through the family network. I wouldn’t be here without his support, courage, and love.

Do you have any pets?

Yes, a lovely Aussiedoodle, Neela. She has been our family’s most adorable, energetic, and loyal addition. We chose her because of my daughter, Meghana Illendula.

What is your favorite vacation/activity?

Spending time with my parents and siblings at my home in India, where I grew up, is my favorite vacation.

Who is the person you admire most, and why?

My father, Dr. Rangaiah Kancharla. He is a veterinarian doctor by training who grew up during India’s post-independence depression period. His significant contributions have strengthened children by providing education, relieving child labor, developing co-ops for farming families, and fighting for farmers’ fair pay policies. He is a bridge between government reforms and people in need. His service is the foundation for my life and current personality. My father’s vision of education, women’s employment, and serving society is the moral pillar for all our siblings’ lives, especially for my Ph.D. My parents provided values of commitment, preservation, and courage to face the challenges.

What is the best advice anyone ever gave you?

“Serve all beings as service to God. Worship your own, and respect all” - My spiritual teacher, HH Sri Chinna Jeeyar Swamy.

Would you rather do one thing extraordinarily well or ten things admirably well?


My scientific training by my Ph.D. mentor, Venkateswarlu Peesapati, and PIs, Professor David W. Boykin, and Professor Mark Kester, and life taught me the incredible skill of doing ten things admirably well. It’s a juggling act, but a focused mind and practice provide this remarkable skill.



Sitting left: Dr. Rangaiah Kancharla, father
Right: Vijayalakshmi Kancharla (mother)
Standing right, Rajini Kancharla (sister)
Middle: Sudheer Kancharla (brother)
Left: myself.

DIVISION OF HEMATOLOGY & ONCOLOGY

CLINICAL FACULTY PROFILE - Muneeb Rehman



Dr. Muneeb Rehman and his wife.

Tell us a little bit about yourself.

I have been at UVa for six months. I started my medical career at The Ohio State University College of Medicine for medical school in Columbus, Ohio. I completed my internal medicine residency at Mayo Clinic in Rochester, Minnesota, and fellowship in Hematology and Medical Oncology at Georgetown University in Washington, DC.

Why Healthcare?

I was drawn to a career in healthcare due to a lifelong love of science and a desire to work closely with patients to provide high-quality care and help patients through trying times. My research interest is driven by my desire to see better patient outcomes. I am interested in cancer therapeutics focusing on drug development and early phase clinical trials, bringing new technologies to improve healthcare systems and healthcare delivery, and improving healthcare access in research-poor settings. I also enjoy working with students and trainees and love the enthusiasm and curiosity they bring to healthcare teams.

What brought you to Charlottesville?

My wife and I sought UVa for the opportunity to provide cutting-edge care, work and learn from excellent peers and mentors, and be part of a warm, collegial, and collaborative working environment. We love hiking, being outdoors, and great food, which made us always intrigued by Charlottesville and has made us love living here.

What excites you about your work?

My excitement about my work comes from the opportunity to work with patients and help them through trying times! I feel honored by the trust given to me to help guide patients through their Oncologic care. I am also excited by research opportunities to bring novel therapies to my patients and work on improving outcomes.

What do you enjoy doing on the weekend?

My wife and I love hiking and trying different foods – cooking together and eating out at various restaurants. We also love traveling – we often take weekend trips to DC, Richmond, and other parts of Virginia. We also love watching movies and TV shows.

What is your favorite vacation/activity spot?

We love cultural trips where we can experience different cultures and food. We went to Japan last June and loved it. I would love to go there again.

Who is the person you admire most, and why?

The person I admire most is my wife because she can balance multiple facets of her life and devote herself fully to each one. She is an ophthalmology resident at UVa, but also is incredibly present, loving, and generous as a wife, daughter, sister, and friend. She is also my go-to person for advice, as she always has the wisdom to provide the correct answer or guidance in any situation.

What is a talent or skill you don't have that you wish you did?

I wish I had a musical or artistic talent. I would love to be able to play an instrument. I played saxophone in middle school but did not keep up with it.

Favorite fictional characters?

I am a big Harry Potter fan and love those three main characters – Harry Potter, Hermione Granger, and Ron Weasley.

Would you rather do one thing extraordinarily well or ten things admirably well?

I would rather do ten things admirably well. I like the idea of being well-balanced with multiple talents/interests.

What is the last book you read for pleasure?

The last book I read for pleasure is Pachinko, a multi-generational story about a Korean family and their journey before, during, and after World War II.

What's the most unusual thing you have ever eaten?

I once ate a fried cricket.

APP PROFILE - Amelia Hodson



Amelia Hodson and husband, Wilby, with our son, Tristan, at his football game.

Tell us a little bit about yourself.

I've been at UVA for 17 years. I started as an associate's degree RN in the NICU and earned my BSN in 2005. Around that time, I found my true calling in Oncology, earned my MSN, and have been part of UVA's Cancer Center ever since!

Why healthcare?

In high school, I knew I enjoyed science and was interested in medicine, so I stumbled into nursing. It took me about eight years into my nursing career to discover my love for Oncology (but that's the great thing about nursing: you can evolve and change your focus and practice easily). In oncology nursing, I've had several roles: an infusion nurse, RN Research Coordinator, inpatient oncology and SCT nurse, and a Hematology/Oncology APP. I've stayed in healthcare these last 18 years because of the patients. Illness is an inescapable part of life, and cancer is truly scary, but it is gratifying to be able to provide help and support to people through the most challenging times of their lives.

What brought you to Charlottesville?

UVA and my husband! It's a cute story. After earning my ADN, I moved to Boston, but my boyfriend didn't follow me. Instead, he transferred his job to Charlottesville because he said he knew I would end up at UVA eventually. As it turned out, he was right! After one year in Boston, I

applied for and accepted a nursing job at UVA, and that boyfriend quickly became my husband! Seventeen years later, we love calling Charlottesville home - though we bought land and built our house about 30 minutes outside of Charlottesville after the first few years of living in town!

What excites you about your work?

I love my job! It is the exact role I dreamed of when I decided to return to school to become a Nurse Practitioner. Before starting my MSN program, I worked with Dr. Keng as a clinical research nurse coordinator in the leukemia clinic for several years. He mentored me and encouraged me to continue my education to become an APP, and I'm forever grateful to him. I work closely with Dr. El Chaer, our Nurse Coordinator Sam, and pharmacist Dr Jones in our Myeloid Malignancy Clinic. Myeloid malignancies are fascinating, and our patients challenge and humble me daily. The most exciting thing is that I've only worked with this disease population in various roles for less than a decade. Still, I'm seeing drastic improvements in available therapies, treatment tolerability, and survival outcomes. In our clinic, we often joke that Dr. El Chaer knows about the most recent practice-changing article less than five minutes after its publication or even pending its publication. He immediately shares that information with the team, but honestly, this is the most exciting part of my work and the team dynamic I'm so lucky to be a part of! Every new study and drug is a step in the right direction. It means hope for the future of patients with a severe diagnosis!



Amelia Hodson and husband, Wilby, with Locksley and Biscuit in front of our barn.

What do you enjoy doing on the weekend?

The weekends just are not long enough! I love many hobbies, but I do not have enough time to do everything I want! One of my biggest hobbies currently is horseback riding. I have always wanted to ride but never did until two years ago when I decided to join my daughter in lessons at a local barn. After a few months of lessons, I was given the opportunity to buy a horse of my own, and it has been quite the experience! Riding and maintaining our little "farm" takes up much of the weekend. I also love family time, gardening, cooking, reading, being outside, long-distance running, and going to our favorite local vineyard (Keswick)!

Do you have any pets?

In addition to my horse, Locksley, I have a German Shepherd named Delta and a miniature donkey named Biscuit. Biscuit is the crowd favorite and the cutest and sweetest creature on earth.

Who is the person you admire most, and why?

At the risk of sounding corny or cliché, I will say the person I admire the most is my husband, Wilby. In 2019, he was diagnosed with stage IVA non-small cell lung cancer. As a young, healthy, non-smoker, this diagnosis was beyond heartbreaking and changed our lives. He has had a very complex course with over two years of nearly continuous chemotherapy, three thoracotomies with a complete lobectomy and several segmentectomies, and four rounds of radiation to date. He never missed coaching our son's little league football games and refused to sit back and take it easy at our daughter's horse shows despite recovering from hard chemo and intense surgeries. He has never allowed cancer to come between him and being the best father and husband. When I decided to bring my horse home, he made my dream his passion. I drew a picture of my ideal barn, and he built it for me. He never hesitated to help me with all the other projects needed to make our home a "little farm." All this is done while missing substantial lung tissue and always looming uncertainty about the future. He rarely missed work throughout all his treatments and is truly loved by his peers and employees. We still live our lives three months at a time, from scan to scan, but Wilby has handled every step of this process with astounding resilience and grace. We have so much love and gratitude for Dr. Hall, Dr. Martin, Dr. Lerner, and Wilby's healthcare team members for getting us to this point. We know our future is in the most capable hands with them.

What is the best advice anyone ever gave you?

"Eyes up, leg on." This is a saying that my riding instructor yells at me often, and although it applies to jumping over fences, I think it translates pretty well to life. Whatever obstacles may come are best handled by looking ahead instead of down and pushing forward instead of shying away.



Amelia Hodson and daughter, Caitlyn, at a horse show.

STAFF PROFILE - Janet Tillage



Tell us a little bit about yourself.

I have been at UVA for a long time. I started as a health unit coordinator in an inpatient unit. After some time, I moved over to Heme Onc. Being at UVA for years in an administrative support role led me to my current position. It also led to me getting my Master's Degree in Health Sciences Administration.

What brought you to Charlottesville?

I was born and raised here in Charlottesville.

What excites you about your work?

Working with my co-workers excites me about my work.

What do you enjoy doing on the weekend?

On the weekends, I enjoy watching sports and hanging out with friends.

What is a talent or skill you don't have that you wish you did?

I wish I could crochet.

Would you rather do one thing extraordinarily well or ten things admirably well?

I would rather do ten things admirably well.

Save the Date for the Michael J. Weber Symposium

Friday, October 11

UVA Cancer Center

*An NCI-Designated Comprehensive
Cancer Center*



The fourth annual Michael J. Weber Symposium will take place on Friday, October 11, 2024, at the UVA Health System (venue to be determined). It will be organized by the University of Virginia Comprehensive Cancer Center (UVACCC) and co-sponsored by the Center for RNA Science and Medicine.

The theme of the symposium is RNA and Cancer.

The symposium will feature five world renowned speakers including a Nobel laureate.

The Michael J. Weber Symposium was established to honor the life and achievements of Michael Weber, a renowned scientist, professor and former UVACCC Director. The symposium aims to bring together cancer researchers and clinicians to present their findings on cancer research, with a focus on integrating basic, translational, and population science research with clinical trials and compassionate patient care.

Questions? Email Erin Erickson at ejh8k@uvahealth.org